<SEC-DOCUMENT>0000947871-19-000957.txt : 20191212
<SEC-HEADER>0000947871-19-000957.hdr.sgml : 20191212
<ACCEPTANCE-DATETIME>20191212171103
ACCESSION NUMBER:		0000947871-19-000957
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20191209
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191212
DATE AS OF CHANGE:		20191212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12215
		FILM NUMBER:		191282568

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ss159854_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:DGX="http://DGX/20191209">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_DGX_DGX_20191209 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20191209_20191209 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001022079 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityCentralIndexKey">0001022079</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="dgx-20191209.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-12-09to2019-12-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022079</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-09</xbrli:startDate>
        <xbrli:endDate>2019-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-align: center">WASHINGTON, DC 20549</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20191209__20191209_zPRQ2v91Rxm9"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CURRENT REPORT PURSUANT TO SECTION 13 OR
15(d) OF</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-align: center"><b>Date of Report</b> (Date of Earliest
Event Reported)<b>: <span id="xdx_908_edei--DocumentPeriodEndDate_c20191209__20191209_zhSlyDFjR7mb"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 9, 2019</ix:nonNumeric></span></b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 6.6pt 0 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20191209__20191209_zBbn3pQ3z3M1"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityRegistrantName">Quest Diagnostics Incorporated</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-align: center">(Exact Name of Registrant as Specified
in Its Charter)</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20191209__20191209_zpcSxpAd0cT2"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-align: center">(State or other jurisdiction of incorporation)</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td colspan="3">&#160;</td></tr>
<tr>
    <td style="width: 39%">&#160;</td>
    <td style="width: 20%">&#160;</td>
    <td style="width: 41%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; text-align: center"><b><span id="xdx_90B_edei--EntityFileNumber_c20191209__20191209_zFyeiDxvSmH3"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityFileNumber">001-12215</ix:nonNumeric></span></b></td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20191209__20191209_zU8y7piz9Bvf"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityTaxIdentificationNumber">16-1387862</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt; text-align: center">(Commission File Number)</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center">(I.R.S. Employer Identification No.)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 2.2pt 1.1pt 1.1pt; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20191209__20191209_zPFKyBpKMHq"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityAddressAddressLine1">500 Plaza Drive</ix:nonNumeric></span></b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 1.1pt; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20191209__20191209_zvlmCGxiI6la"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityAddressCityOrTown">Secaucus</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20191209__20191209_z0VJcnY8QJqb"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></p></td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt; text-align: center"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20191209__20191209_z7xfHfaWPW07"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:EntityAddressPostalZipCode">07094</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 1.1pt; padding-right: 1.1pt; padding-left: 1.1pt; text-align: center">(Address of principal executive offices)</td>
    <td style="padding-right: 1.1pt; padding-left: 1.1pt; text-align: center">&#160;</td>
    <td style="padding-top: 1.1pt; padding-right: 1.1pt; padding-left: 1.1pt; text-align: center">(Zip Code)</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td>
    <td style="padding: 1.1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding: 1.1pt; text-align: center"><b><span id="xdx_904_edei--CityAreaCode_c20191209__20191209_zQKLTB5aFEQ5"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:CityAreaCode">(973)</ix:nonNumeric></span> <span id="xdx_904_edei--LocalPhoneNumber_c20191209__20191209_zVKidhmpfCU9"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:LocalPhoneNumber">520-2700</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="padding: 1.1pt; text-align: center">(Registrant&#8217;s telephone number, including area code)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="width: 100%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; padding: 1.1pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.4pt 0 0">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20191209__20191209_zWlc4SQRtn16"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">o</ix:nonNumeric></span></span> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20191209__20191209_zaeXShw4OVOj"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">o</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20191209__20191209_zkVSStxVPDed"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">o</ix:nonNumeric></span></span> Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Wingdings"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20191209__20191209_zCfWzmdy7uC2"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">o</ix:nonNumeric></span></span> Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Title of each class</td>
    <td style="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Trading Symbol(s)</td>
    <td style="width: 42%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Name of each exchange on which registered</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_902_edei--Security12bTitle_c20191209__20191209_z2ne4fd0X5Qd"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:Security12bTitle">Common Stock, $0.01 Par Value</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_901_edei--TradingSymbol_c20191209__20191209_z9GHGQgot1L9"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" name="dei:TradingSymbol">DGX</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span id="xdx_909_edei--SecurityExchangeName_c20191209__20191209_z4BYKACIy2hg"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20191209__20191209_zFj0UMQqaMr5"><ix:nonNumeric contextRef="From2019-12-09to2019-12-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">o</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">o</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>
<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item 8.01 Other Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On December 9, 2019, Quest Diagnostics Incorporated (the
&#8220;Company&#8221;) issued a press release announcing the pricing of a public offering of $800 million aggregate principal amount
of its 2.950% senior notes due 2030 (the &#8220;Notes&#8221;) under the Company&#8217;s shelf registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company expects to receive the net offering proceeds
upon closing on December 16, 2019, subject to customary closing conditions. The Company intends to use the net proceeds from the
offering to repay at maturity or redeem its 4.750% senior notes due 2020 and 2.500% senior notes due 2020 and for general corporate
purposes. This Current Report on Form 8-K is not a notice of redemption. Any notice of redemption will be made in accordance with
the applicable provisions of the indenture governing such notes. A copy of the press release, dated December 9, 2019, is attached
to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In connection with the offering of the Notes, on December
9, 2019, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities
LLC, Morgan Stanley &#38; Co. LLC and Wells Fargo Securities, LLC on behalf of themselves and the other underwriters named therein.
The Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated by reference into
this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item&#160;9.01 Financial Statements and Exhibits</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="width: 10%; padding-right: 5.75pt; padding-bottom: 10pt; padding-left: 5.75pt; text-align: right"><b><span style="text-decoration: underline">Exhibit</span></b></td>
    <td style="width: 81%; padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><b><span style="text-decoration: underline">Description</span></b></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt; text-align: right"><a href="ss159854_ex0101.htm">1.1</a></td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss159854_ex0101.htm">Underwriting Agreement, dated December 9, 2019.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt; text-align: right"><a href="ss159854_ex9901.htm">99.1</a></td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt"><a href="ss159854_ex9901.htm">Press Release issued by the Company, dated December 9, 2019, announcing pricing of notes.</a></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt">&#160;</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 5.75pt; text-align: right">104</td>
    <td style="padding-right: 5.75pt; padding-bottom: 0.1in; padding-left: 12.6pt">The cover page from this current report on Form 8-K, formatted in Inline XBRL.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b>Signature</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.25in">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 243.35pt; text-indent: -27.35pt">December 12, 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 243.35pt; text-indent: -27.35pt">QUEST DIAGNOSTICS INCORPORATED</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 243.35pt; text-indent: -27.35pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 216pt"></td><td style="width: 27.35pt">By:</td><td style="border-bottom: Black 1pt solid">/s/ William J. O&#8217;Shaughnessy, Jr. </td></tr>                                                                                                                                       <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>William J. O&#8217;Shaughnessy, Jr.</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>Deputy General Counsel and Corporate Secretary</td></tr>
</table>

<p style="font: 10pt inherit,serif; margin: 0 0 10pt 243.35pt; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->





<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFTc0KgkAQfgLfYdizmFod8piURBYhEV2XHGNJd2R2tXqk3rJViYYPhpnvTwhfZLRVNTJc10UOZ2zaWlqEAitk1Dd0inS3T8DtAu/KWJbajufPmJLzoPMsg+jm/qOyVwbLBKJ4NmAF4SKZh3A6CG/gU9KVKlFbJWuQuoQTU8sKreT3lHCWL9LUvMemC7JRpF1cEE70B+IwiuFIvXwSPwzkeSo8fxxPZExdO9R0xlIDmxob12Um6x/eF9u2SRY= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ss159854_ex0101.htm
<DESCRIPTION>UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXECUTION COPY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 132pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.5in; text-align: center">QUEST DIAGNOSTICS INCORPORATED<BR>
(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">$800,000,000 2.950% Senior Notes due 2030</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 156pt; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Dated: December 9, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><U>Page</U></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 1.&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0pt; padding-bottom: 0pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Representations and Warranties by the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">3</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Officer&#8217;s Certificates</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 2.&nbsp;&nbsp;&nbsp;<U>Sale and Delivery to Underwriters; Closing</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Notes</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Public Offering</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Payment</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Denominations; Registration</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 3.&nbsp;&nbsp;&nbsp;<U>Covenants of the Company</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">14</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Amendments and Supplements</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Free Writing Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Free Writing Prospectus (Underwriter)</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(e)&nbsp;&nbsp;&nbsp;<I>Amend or Supplement Time of Sale Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(f)&nbsp;&nbsp;&nbsp;<I>Amend or Supplement Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(g)&nbsp;&nbsp;&nbsp;<I>Blue Sky Qualifications</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(h)&nbsp;&nbsp;&nbsp;<I>Rule 158</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(i)&nbsp;&nbsp;&nbsp;<I>Use of Proceeds</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(j)&nbsp;&nbsp;&nbsp;<I>Restriction on Sale of Notes</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(k)&nbsp;&nbsp;&nbsp;<I>Final Term Sheet</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(l)&nbsp;&nbsp;&nbsp;<I>Reporting Requirements</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(m)&nbsp;&nbsp;&nbsp;<I>DTC Clearance</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 4.&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Expenses</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 5.&nbsp;&nbsp;&nbsp;<U>Conditions of Underwriters&#8217; Obligations</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">17</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Opinion of Deputy General Counsel of the Company</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for the Underwriters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Officers&#8217; Certificate</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(e)&nbsp;&nbsp;&nbsp;<I>Prospectus, Final Term Sheet and Free Writing Prospectus</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">18</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(f)&nbsp;&nbsp;&nbsp;<I>Comfort Letters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(g)&nbsp;&nbsp;&nbsp;<I>Maintenance of Rating</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(h)&nbsp;&nbsp;&nbsp;<I>Twentieth Supplemental Indenture</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(i)&nbsp;&nbsp;&nbsp;<I>Additional Documents</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">19</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in; width: 90%">(j)&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt; width: 10%">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 6.&nbsp;&nbsp;&nbsp;<U>Covenants of the Underwriters</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">19</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 7.&nbsp;&nbsp;&nbsp;<U>Indemnification</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Indemnification of the Underwriters</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Indemnification of Company, Directors and Officers</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">20</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(c)&nbsp;&nbsp;&nbsp;<I>Actions against Parties; Notification</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(d)&nbsp;&nbsp;&nbsp;<I>Settlement without Consent if Failure to Reimburse</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 8.&nbsp;&nbsp;&nbsp;<U>Contribution</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">22</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 9.&nbsp;&nbsp;&nbsp;<U>Representations, Warranties and Agreements to Survive Delivery</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 10.&nbsp;&nbsp;&nbsp;<U>Termination of Agreement</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>Termination; General</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>Liabilities</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 11.&nbsp;&nbsp;&nbsp;<U>Default by One or More of the Underwriters</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 12.&nbsp;&nbsp;&nbsp;<U>Default by the Company</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 13.&nbsp;&nbsp;&nbsp;<U>Notices</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">24</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 14.&nbsp;&nbsp;&nbsp;<U>Parties</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 15.&nbsp;&nbsp;&nbsp;<U>Governing Law and Time</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 16.&nbsp;&nbsp;&nbsp;<U>Effect of Headings</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 17.&nbsp;&nbsp;&nbsp;<U>Partial Unenforceability</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 18.&nbsp;&nbsp;&nbsp;<U>No Advisory or Fiduciary Responsibility</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">25</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 19.&nbsp;&nbsp;&nbsp;<U>Recognition of the U.S. Special Resolution Regimes</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">26</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">SECTION 20.&nbsp;&nbsp;&nbsp;<U>General Provisions</U></TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">27</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0pt; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(a)&nbsp;&nbsp;&nbsp;<I>General</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">27</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in">(b)&nbsp;&nbsp;&nbsp;<I>USA Patriot Act</I></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">27</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule A</TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="width: 82%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Underwriters</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule B</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Time of Sale Prospectus</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule C-1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Purchase Price</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule C-2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Final Term Sheet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Schedule D</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Subsidiaries</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Exhibit A</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Form of Opinion of Shearman &amp; Sterling LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Exhibit B</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">-</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Form of Opinion of Deputy General Counsel of the Company</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">QUEST DIAGNOSTICS INCORPORATED<BR>
(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">$800,000,000 2.950% Senior Notes due 2030</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: right">December 9, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MORGAN STANLEY &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">WELLS FARGO SECURITIES, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><BR>
c/o J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">383 Madison Ave., 6<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">c/o MORGAN STANLEY &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1585 Broadway, 29<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">c/o WELLS FARGO SECURITIES, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">550 South Tryon Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Charlotte, NC 28202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Quest Diagnostics
Incorporated, a Delaware corporation (the &#8220;Company&#8221;) confirms its agreement with J.P. Morgan Securities LLC (&#8220;JPMorgan&#8221;),
Morgan Stanley &amp; Co. LLC (&#8220;Morgan Stanley&#8221;), Wells Fargo Securities, LLC (&#8220;Wells Fargo&#8221;), Goldman Sachs
&amp; Co. LLC, Mizuho Securities USA LLC and each of the other underwriters named in Schedule A hereto (collectively, the &#8220;Underwriters,&#8221;
which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;11 hereof), for whom JPMorgan,
Morgan Stanley and Wells Fargo are acting as representatives (in such capacity, the &#8220;Representatives&#8221;), with respect
to the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective
principal amounts set forth in said Schedule&nbsp;A of $800,000,000 aggregate principal amount of the Company&#8217;s 2.950% Senior
Notes due 2030 (the &#8220;Notes&#8221;). The Notes are to be issued pursuant to an indenture dated as of June 27, 2001 (the &#8220;Base
Indenture&#8221;) among the Company, the Subsidiary Guarantors party thereto, as guarantors, and The Bank of New York Mellon Trust
Company, N.A., as successor trustee to The Bank of New York (the &#8220;Trustee&#8221;), as supplemented by a first supplemental
indenture, dated as of June 27, 2001, among the Company, as issuer, the Initial Subsidiary Guarantors party thereto and the Trustee,
as further supplemented by a second supplemental indenture, dated as of November 26, 2001, among the Company, the Subsidiary Guarantors
party thereto and the Trustee, as further supplemented by a third supplemental indenture, dated as of April 4, 2002,</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">among the
Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a fourth supplemental indenture,
dated as of March 19, 2003, among the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented
by a fifth supplemental indenture, dated as of April 16, 2004, among the Company, the additional Subsidiary Guarantor party thereto
and the Trustee, as further supplemented by a sixth supplemental indenture, dated as of October 31, 2005, among the Company, the
Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a seventh supplemental indenture, dated as of November
31, 2005, among the Company, the Subsidiary Guarantors party thereto and the Trustee, as further supplemented by an eighth supplemental
indenture, dated as of July 31, 2006, among the Company, the Subsidiary Guarantors party thereto and the Trustee, as further supplemented
by a ninth supplemental indenture, dated as of September 30, 2006, among the Company, the Subsidiary Guarantors party thereto and
the Trustee, as further supplemented by a tenth supplemental indenture, dated as of June 22, 2007, among the Company, the Subsidiary
Guarantors party thereto and the Trustee, as further supplemented by an eleventh supplemental indenture, dated as of June 22, 2007,
among the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a twelfth supplemental
indenture, dated as of June 25, 2007, among the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as
further supplemented by a thirteenth supplemental indenture, dated as of November 17, 2009, among the Company, the Subsidiary Guarantors
party thereto and the Trustee, as further supplemented by a fourteenth supplemental indenture, dated as of March 24, 2011, among
the Company, the additional Subsidiary Guarantors party thereto and the Trustee, as further supplemented by a fifteenth supplemental
indenture, dated as of November 30, 2011, among the Company, the additional Subsidiary Guarantors party thereto and the Trustee,
as further supplemented by a sixteenth supplemental indenture dated as of March 17, 2014, between the Company and the Trustee,
as further supplemented by a seventeenth supplemental indenture, dated as of March 10, 2015, between the Company and the Trustee,
as further supplemented by an eighteenth supplemental indenture dated as of May 23, 2016, between the Company and the Trustee,
as further supplemented by a nineteenth supplemental indenture dated as of March 12, 2019 and as to be further supplemented by
a twentieth supplemental indenture to be dated December 16, 2019, between the Company and the Trustee (the &#8220;Twentieth Supplemental
Indenture&#8221;); the Base Indenture together with all such supplements, the &#8220;Indenture&#8221;. The Notes will be issued
only in book-entry form in the name of Cede &amp; Co., as nominee of The Depository Trust Company (the &#8220;Depositary&#8221;)
pursuant to a letter of representations, dated October 27, 2005 (the &#8220;DTC Agreement&#8221;), between the Company and the
Depositary.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Company
has filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) a registration statement, including a prospectus,
(the file number of which is 333-232138) on Form S-3, relating to securities (the &#8220;Shelf Securities&#8221;), including the
Notes, to be issued from time to time by the Company. The registration statement as amended to the date of this Agreement, including
the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A or
Rule 430B under the Securities Act of 1933, as amended (the &#8220;1933 Act&#8221;), is hereinafter referred to as the &#8220;Registration
Statement&#8221;, and the related prospectus covering the Shelf Securities dated June 14, 2019 is hereinafter referred to as the
&#8220;Basic Prospectus&#8221;. The Basic Prospectus, as supplemented by the prospectus supplement specifically relating to the
Notes in the form first used to confirm sales of the Notes (or in the form first made available to the Underwriters by the Company
to meet requests of purchasers pursuant to Rule 173 under the 1933 Act) is hereinafter referred to as the &#8220;Prospectus&#8221;,
and the term &#8220;preliminary prospectus&#8221; means any preliminary form of the Prospectus.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">For purposes of this Agreement,
&#8220;free writing prospectus&#8221; has the meaning set forth in Rule 405 under the 1933 Act and &#8220;Time of Sale Prospectus&#8221;
means the preliminary prospectus identified in Schedule B hereto together with the free writing prospectuses, if any, each identified
in Schedule B hereto. As used herein, the terms &#8220;Registration Statement&#8221;, &#8220;Basic Prospectus&#8221;, &#8220;preliminary
prospectus&#8221;, &#8220;Time of Sale Prospectus&#8221; and &#8220;Prospectus&#8221; shall include the documents, if any, incorporated
by reference therein. The terms &#8220;supplement&#8221;, &#8220;amendment&#8221; and &#8220;amend&#8221; as used herein with respect
to the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus or free writing prospectus
shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934,
as amended (the &#8220;1934 Act&#8221;), that are deemed to be incorporated by reference therein.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">All references
in this Agreement to financial statements and schedules and other information which is &#8220;contained&#8221;, &#8220;included&#8221;,
&#8220;stated&#8221;, &#8220;described&#8221; or &#8220;disclosed&#8221; in the Registration Statement, the Basic Prospectus, the
Time of Sale Prospectus, any preliminary prospectus or free writing prospectus (or other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information which are incorporated by reference in the
Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus or free writing prospectus,
as the case may be.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 1.&#9;<U>Representations
and Warranties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations
and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of the date hereof and as of the
Closing Time referred to in Section 2(c) hereof (unless otherwise specified), and agrees with each Underwriter, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Registration Statement has become effective, no stop order suspending the effectiveness of the Registration Statement is in effect
and no proceedings for such purpose are pending before or threatened by the Commission. The Company is a well-known seasoned issuer
(as defined in Rule 405 under the 1933 Act), eligible to use the Registration Statement as an automatic shelf registration statement
and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(A)
The Registration Statement, when it became effective, did not contain, and as amended or supplemented, if applicable, will not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, (B) the Registration Statement as of the date hereof does not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (C) the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable, will comply
in all material respects with the 1933 Act and the applicable rules and regulations of the Commission thereunder, (D) the Time
of Sale Prospectus does not, and at the time of each sale of the Notes in connection with the offering when the Prospectus is not
yet available to prospective purchasers and at the Closing Time, the Time of Sale Prospectus, as then amended or supplemented by
the Company, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify">(E) each electronic
road show related to the offering of the Notes, if any, when considered together with the Time of Sale Prospectus, does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading and (F) the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 85.5pt">The
representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement,
the Time of Sale Prospectus or the Prospectus made in reliance upon and in conformity with information furnished to the Company
in writing by any Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Incorporated
Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Time of Sale Prospectus or the Prospectus,
at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements
of the 1934 Act and the rules and regulations of the Commission thereunder (the &#8220;1934 Act Regulations&#8221;), and, when
read together with the other information in the Time of Sale Prospectus or the Prospectus at its date and at the Closing Time,
did not and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company is not an &#8220;ineligible issuer&#8221; in connection with the offering pursuant to Rules 164, 405 and 433 under the
1933 Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the 1933 Act has been,
or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the applicable rules and regulations
of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule
433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in
all material respects with the requirements of the 1933 Act and the applicable rules and regulations of the Commission thereunder.
Except for the free writing prospectuses, if any, identified in Schedule B hereto, and electronic road shows each furnished to
you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use
or refer to, any free writing prospectus. Any issuer free writing prospectus as defined in Rule 433(h) under the 1933 Act, as of
its issue date and at all subsequent times through the completion of the public offer and sale of the Notes, did not, does not
and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, including any document incorporated by reference therein and any preliminary
or other prospectus deemed to be a part thereof that has not been superseded or modified.</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Independent
Accountants</U>. PricewaterhouseCoopers LLP, which audited the annual financial statements incorporated by reference in the Time
of Sale Prospectus and the Prospectus, are independent registered public accountants with respect to the Company, in any case,
as required by the 1933 Act, the rules and regulations of the Commission under the 1933 Act, the 1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Financial
Statements</U>. The financial statements of the Company included or incorporated by reference in the Time of Sale Prospectus and
the Prospectus, together with the related schedule and notes, present fairly (A) the financial position of the Company and its
Subsidiaries (as defined below) on a consolidated basis at the dates indicated and (B) the statements of operations, stockholders&#8217;
equity and cash flows of the Company and its Subsidiaries on a consolidated basis for the periods specified. Such financial statements
have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) applied
on a consistent basis throughout the periods involved. The supporting schedules relating to the Company, if any, included in the
Time of Sale Prospectus and the Prospectus present fairly in accordance with GAAP the information required to be stated therein.
The summary financial information of the Company included in the Time of Sale Prospectus and the Prospectus present fairly the
information shown therein and have been compiled on a basis consistent with that of the audited or unaudited financial statements
of the Company, as applicable, included in the Time of Sale Prospectus and the Prospectus. The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus
fairly present the information called for in all material respects and have been prepared in all material respects in accordance
with the Commission&#8217;s rules and guidelines applicable thereto. There are no historical or pro forma financial statements
of the Company or any of its Subsidiaries or any acquired entities which are required by the 1933 Act to be disclosed in the Registration
Statement, the Time of Sale Prospectus or the Prospectus which are not so disclosed in the Registration Statement, the Time of
Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Material Adverse Change in Business</U>. Since the respective dates as of which information is given in the Time of Sale Prospectus,
except as otherwise stated therein or contemplated thereby, (A)&nbsp;there has been no material adverse change in the business,
financial condition, operations, cash flow or business prospects of the Company and its Subsidiaries, considered as one enterprise,
whether or not arising in the ordinary course of business (a &#8220;Material Adverse Effect&#8221;), and (B)&nbsp;there have been
no transactions entered into by the Company or any of its Subsidiaries, other than those described or contemplated by the Time
of Sale Prospectus or in the ordinary course of business, which are material with respect to the Company and its Subsidiaries considered
as one enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Good
Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under
the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under
this Agreement, the Indenture and the Notes; and the Company is duly qualified as a foreign corporation to transact business and
is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Good
Standing of Subsidiaries</U>. Each subsidiary of the Company (each a &#8220;Subsidiary&#8221; and collectively the &#8220;Subsidiaries&#8221;)&nbsp;has
been duly organized and is validly existing as a corporation, partnership or limited liability company, as the case may be, in
good standing under the laws of the jurisdiction of its incorporation or existence, has corporate or partnership power and authority
to own, lease and operate its properties and to conduct its business as described in the Time of Sale Prospectus and the Prospectus
and is duly qualified as a foreign corporation or partnership to transact business and is in good standing in each jurisdiction
in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business,
except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise
disclosed in the Time of Sale Prospectus and the Prospectus, all of the outstanding capital stock or partnership interests of each
Subsidiary have been duly authorized and validly issued or created, are fully paid and non-assessable and except as described in
Schedule D are owned by the Company, directly or through the Subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance, claim or equity; none of the outstanding shares of capital stock or partnership interests of the Subsidiaries
was issued in violation of any preemptive or similar rights arising by operation of law, or under the charter, by-laws or other
charter documents of any Subsidiary or under any agreement to which the Company or any Subsidiary is a party. All of the Subsidiaries
of the Company are listed on Schedule D attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by, and will be a valid and binding agreement
of, the Company, enforceable in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Qualification,
Authorization and Description of the Indenture</U>. The Indenture has been duly qualified under the Trust Indenture of 1939, as
amended. The Base Indenture and each supplemental indenture thereto have all been duly authorized, executed and delivered by the
Company (and each of the Subsidiaries party thereto, as applicable) and constitute valid and binding agreements of the Company
(and each of the Subsidiaries party thereto, as applicable), enforceable against the Company (and each of the Subsidiaries party
thereto, as applicable) in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or at law). The Twentieth Supplemental Indenture has been duly authorized
by the Company and, when duly executed and delivered by the Company, will constitute a valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency
(including, without limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors&#8217; rights generally and except as enforcement thereof is subject to general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization
of the Notes</U>. The Notes to be purchased by the Underwriters from the Company have been duly authorized for issuance and sale
to the Underwriters pursuant to this Agreement and, at the Closing Time, will have been duly executed by the Company and, when
authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of the purchase price
therefor as provided in this Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company
in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency (including, without
limitation, all laws relating to fraudulent transfers), reorganization, moratorium or similar laws affecting enforcement of creditors&#8217;
rights generally and except as enforcement thereof is subject to general principles of equity (regardless of whether enforcement
is considered in a proceeding in equity or at law), and will be in the form contemplated by, and entitled to the benefits of, the
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Description
of the Notes and the Indenture</U>. The description of the Notes and the Indenture set forth in the Time of Sale Prospectus and
the Prospectus are correct and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Guarantor
Subsidiaries</U>. Except as otherwise disclosed in the Time of Sale Prospectus and the Prospectus, no Subsidiary (A) is a guarantor
of any Indebtedness (as defined in the Indenture) of the Company that, when taken together with any other outstanding Indebtedness
of the Company that is guaranteed by its Subsidiaries that are not Subsidiary Guarantors (as defined in the Indenture), exceeds
$50 million in the aggregate at any time, or (B) has incurred any Indebtedness that is not permitted pursuant to Section 1011 of
the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Defaults and Conflicts</U>. Neither the Company nor any of the Subsidiaries is in violation of its charter or by-laws or in
default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture,
mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of
the Subsidiaries is a party or by which any of them may be bound, or to which any of the property or assets of the Company or any
of the Subsidiaries is subject (collectively, &#8220;Agreements and Instruments&#8221;)&nbsp;or has violated or is in violation
of any of the laws, rules and regulations administered by the United States Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;),
the United States Food and Drug Administration (the &#8220;FDA&#8221;), the Substance Abuse and Mental Health Services Administration
(the &#8220;SAMHSA&#8221;) and by the Drug Enforcement Administration (the &#8220;DEA&#8221;), or any other applicable law, statute,
rule, regulation, judgment, order, writ or decree of any government, government instrumentality or court, domestic or foreign,
having jurisdiction over the Company or any of the Subsidiaries or any of their assets or properties, except in each case for such
defaults or violations that have been disclosed or that would not singly or in the aggregate result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify">The execution, delivery and performance of this Agreement, the Indenture, the Notes and any other agreement or instrument entered
into or issued or to be entered into or issued by the Company in connection with the consummation of the transactions contemplated
by this Agreement herein and in the Time of Sale Prospectus and the Prospectus (including the issuance and sale of the Notes, the
use of the proceeds from the sale of the Notes as described in the Time of Sale Prospectus and the Prospectus under the caption
&#8220;Use of Proceeds&#8221;) and compliance by the Company with its obligations under this Agreement, the Indenture and the Notes
have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice
or passage of time or both, conflict with or constitute a breach of, or a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any property or assets of the Company or any of the Subsidiaries pursuant to, the Agreements
and Instruments (except for such conflicts, breaches or defaults or liens, charges or encumbrances that, singly or in the aggregate,
would not result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter or
by&#45;laws of the Company or any of the Subsidiaries or any applicable law, statute, rule, regulation, judgment, order, writ or
decree of any government, government instrumentality or court, domestic or foreign, having jurisdiction over the Company or any
of the Subsidiaries or any of their assets, properties or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Labor Disputes</U>. No labor dispute with the employees of the Company or any of the Subsidiaries exists or, to the knowledge
of the Company, is imminent, which may reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Proceedings</U>. Except as disclosed in the Time of Sale Prospectus and the Prospectus or in the documents incorporated by reference
thereto, there is not pending or, to the knowledge of the Company, threatened any action, suit, proceeding, inquiry or investigation,
to which the Company or any Subsidiary is a party, or to which the property of the Company or any Subsidiary is subject, before
or brought by any domestic or foreign court or governmental agency or body, affecting (A) the possession by any of them of any
Governmental Authorization (as defined herein) currently held by any them, (B) the accreditation of any of their respective laboratories
with the College of American Pathologists (&#8220;CAP&#8221;), (C) any of their qualification to perform services for and receive
reimbursement from, Medicaid, Medicare or TRICARE (D) any of their ability to conduct their clinical testing business in any state
or (E) any of them in any other way, which in the case of any of the foregoing, might reasonably be expected to result in a Material
Adverse Effect, or which might reasonably be expected to materially and adversely affect the properties or assets of the Company
and the Subsidiaries considered as one enterprise or the consummation of the transactions contemplated in this Agreement or the
performance by the Company of its obligations hereunder or under the Indenture or the Notes. The aggregate of all pending legal
or governmental proceedings to which the Company or any Subsidiary thereof is a party or of which any of their respective property
or assets is the subject which are not described in the Time of Sale Prospectus and the Prospectus or in the documents incorporated
by reference thereto, including ordinary routine litigation incidental to the business, could not reasonably be expected to result
in a Material Adverse Effect. All of the descriptions set forth in the Time of Sale Prospectus and the Prospectus or in the documents
incorporated by reference thereto, of the legal and governmental proceedings by or before any court, governmental agency or body
are true and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Time of Sale Prospectus and the
Prospectus or the documents incorporated by reference therein or to be filed as exhibits to the Registration Statement which have
not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Possession
of Intellectual Property</U>. The Company and the Subsidiaries own, possess or license, or can acquire on reasonable terms, adequate
patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property
(collectively, &#8220;Intellectual Property&#8221;)&nbsp;necessary to carry on the business now operated by them, and neither the
Company nor any of the Subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted
rights of others with respect to any Intellectual Property (including Intellectual Property which is licensed)&nbsp;or of any facts
or circumstances which would render any Intellectual Property invalid or inadequate to protect the interest of the Company or any
of the Subsidiaries therein, and which infringement or conflict or invalidity or inadequacy, singly or in the aggregate, would
reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or
decree of, any court or governmental authority or agency is necessary or required (i) for the performance by the Company of its
obligations hereunder, (ii) in connection with the offering, issuance or sale of the Notes under this Agreement or the consummation
of the transactions contemplated by this Agreement or (iii) for the due execution, delivery or performance by the Company of this
Agreement, the Indenture, the Notes or any other agreement or instrument entered into or issued or to be entered into or issued
by the Company or any of the Subsidiaries in connection with the consummation of the transactions contemplated herein and in the
Time of Sale Prospectus and the Prospectus (including the issuance and sale of the Notes and the use of proceeds from the sale
of the Notes as described in the Time of Sale Prospectus and the Prospectus under the caption &#8220;Use of Proceeds&#8221;), except
such as have been already obtained or as may be required under state securities laws and except such where the failure to obtain
would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Possession
of Licenses, Provider Agreements and Permits</U>. The Company and the Subsidiaries possess all governmental permits, licenses,
provider numbers and agreements, approvals, consents, certificates and other authorizations required (i) under the Medicare, Medicaid
and TRICARE programs, (ii) under the Clinical Laboratories Improvement Act of 1967, as amended (the &#8220;CLIA&#8221;), (iii)
by the SAMHSA and (iv) as otherwise necessary to conduct the business now operated by them respectively, issued by CMS, the FDA,
the SAMHSA and each other appropriate federal, state, local or foreign regulatory agencies or bodies including, but not limited
to, any foreign regulatory authorities performing functions similar to their respective functions (&#8220;Governmental Authorizations&#8221;)
except where failure to obtain such Governmental Authorizations would not, singly or in the aggregate, result in a Material Adverse
Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify">the Company and the Subsidiaries are in compliance with the terms and conditions of all such Governmental Authorizations
and with the rules and regulations of the regulatory authorities and governing bodies having jurisdiction with respect thereto,
except where the failure so to comply would not, singly or in the aggregate, have a Material Adverse Effect; all of the Governmental
Authorizations are valid and in full force and effect, except when the invalidity of such Governmental Authorizations or the failure
of such Governmental Authorizations to be in full force and effect would not have a Material Adverse Effect; and, except as disclosed
in the Time of Sale Prospectus and the Prospectus or in the documents incorporated by reference thereto, neither the Company nor
any of the Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such Governmental
Authorizations, nor are there, to the knowledge of the Company, any pending or threatened actions, suits, claims or proceedings
against the Company or any Subsidiary before any court, governmental agency or body including, but not limited to, CMS, the FDA
and the SAMHSA or otherwise that would reasonably be expected to limit, revoke, cancel, suspend or cause not to be renewed any
Governmental Authorizations, in each case, which, singly or in the aggregate, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Licensing
and Accreditation of Laboratories</U>. All of the regional laboratories of the Company and the Subsidiaries are eligible for accreditation
by CAP and are so accredited, and all of the laboratories of the Company and the Subsidiaries are in compliance, in all material
respects, with the standards required by CLIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Title
to Property</U>. The Company and the Subsidiaries have valid title to all real property owned by the Company and the Subsidiaries
and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests,
claims, restrictions or encumbrances of any kind except such as (a)&nbsp;are described in the Time of Sale Prospectus and the Prospectus
and reflected in the financial statements included therein or (b)&nbsp;do not, singly or in the aggregate, materially affect the
value of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of
the Subsidiaries; and all of the leases and subleases material to the business of the Company and the Subsidiaries, considered
as one enterprise, and under which the Company or any of the Subsidiaries holds properties described in the Time of Sale Prospectus
and the Prospectus, are in full force and effect. Except as described in the Time of Sale Prospectus and the Prospectus, neither
the Company nor any of the Subsidiaries has any notice of any claim of any sort that has been asserted by anyone adverse to the
rights of the Company or any of the Subsidiaries under any of the leases or subleases mentioned above, or affecting or questioning
the rights of the Company or any Subsidiary to the continued possession of the leased or subleased premises under any such lease
or sublease, which, singly or in the aggregate, would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance</U>.
The Company and the Subsidiaries carry or are entitled to the benefits of insurance, including, without limitation, professional
liability insurance, with financially sound and reputable insurers, in such amounts, containing such deductibles and covering such
risks as is reasonable and prudent in the view of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Environmental
Laws</U>. Except for such matters as would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither
the Company nor any of the Subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial
or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without
limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, medical specimens, petroleum or petroleum products or nuclear or radioactive material (collectively,
&#8220;Hazardous Materials&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &#8220;Environmental Laws&#8221;), (B)&nbsp;the Company and the Subsidiaries
have all permits, licenses, authorizations and approvals currently required for their respective businesses under any applicable
Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or threatened administrative,
regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation
or proceedings relating to any Environmental Law against the Company or any of the Subsidiaries and (D)&nbsp;there are no events,
facts or circumstances that might reasonably be expected to form the basis of any liability or obligation of the Company or any
of the Subsidiaries, including, without limitation, any order, decree, plan or agreement requiring clean-up or remediation, or
any action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of
the Subsidiaries relating to any Hazardous Materials or Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration
Rights</U>. Except as disclosed in the Time of Sale Prospectus and the Prospectus or the documents incorporated by reference therein,
there are no holders of securities (debt or equity) of the Company, or holders of rights (including, without limitation, preemptive
rights), warrants or options to obtain securities of the Company, who have the right to request the Company to register securities
held by them under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Sarbanes-Oxley</U>. There is not and, since the end of the period covered by the annual financial statements incorporated
by reference in the Time of Sale Prospectus and the Prospectus, there has not been any failure on the part of the Company and its
Subsidiaries and their respective officers and directors to comply with the applicable provisions of the Sarbanes-Oxley Act of
2002 (the &#8220;Sarbanes-Oxley Act&#8221;, which term, as used herein, includes the rules and regulations of the Commission promulgated
thereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Accounting
Controls</U>. The Company and its consolidated Subsidiaries maintain a system of internal accounting controls that is in compliance
with the Sarbanes-Oxley Act and is sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance
with management&#8217;s general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted
only in accordance with management&#8217;s general or specific authorization; and (D)&nbsp;the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investment
Company Act</U>. The Company is not, and will not be as a result of the sale of the Notes pursuant to this Agreement, an investment
company within the meaning of the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reporting
Company</U>. The Company is subject to the reporting requirements of Section 13 or Section 15(d) of the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Related
Party Transactions</U>. All transactions required to be disclosed under Item 404 of Regulation S-K under the 1933 Act have been
disclosed in the Time of Sale Prospectus and the Prospectus or the Company&#8217;s filings with the Commission under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Unlawful Payments</U>. Neither the Company nor any of its Subsidiaries nor any director, officer, or employee of the Company or
any of its Subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on
behalf of the Company or any of its subsidiaries has (i) used any funds for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization
of any direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee,
including of any government-owned or controlled entity or of a public international organization, or any person acting in an official
capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office;
(iii) materially violated or is in material violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery
or anti-corruption laws; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other
unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper
payment or benefit. The Company and its Subsidiaries have instituted, and maintain and enforce, policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions
where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the &#8220;Money
Laundering Laws&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify">No action, suit or proceeding by or before any court or governmental or regulatory agency, authority or
body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or,
to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Conflict with OFAC Laws or Other Sanctions</U>. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company,
any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is currently subject to any U.S.
sanctions administered by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S.
Department of the Treasury (&#8220;OFAC&#8221;), or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;);
and the Company will not knowingly directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make
available such proceeds, to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities
of any person currently subject to any Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cybersecurity
and Privacy</U>. Except as disclosed in the Time of Sale Prospectus and the Final Prospectus or except as would not, individually
or in the aggregate, have a Material Adverse Effect, (i) the Company and its Subsidiaries are presently, and since the Company&#8217;s
and its Subsidiaries&#8217; inception have been, in compliance with all privacy policies required by applicable laws, contractual
obligations, applicable state, federal and international laws (including without limitation, if and to the extent applicable, the
Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act, and the European Union General Data Protection Regulation), statutes, judgments, orders, rules and regulations of any
court or arbitrator or other governmental or regulatory authority (&#8220;Data Security Obligations&#8221;); (ii) there is no pending,
or to the knowledge of the Company, threatened, action, suit or proceeding by or before any court or governmental agency, authority
or body pending or threatened alleging non-compliance with any Data Security Obligation; (iii) the Company and its Subsidiaries
have established and maintained reasonable data privacy incident response plans consistent with industry standard practices, which
are designed to reasonably respond data security incidents in accordance with the Data Security Obligations; (iv) the Company is
taking reasonable steps to comply with the California Consumer Privacy Act when such act takes effect with respect to the Company
and its Subsidiaries; (v) the Company and its Subsidiaries have taken all reasonable actions to comply with all applicable laws
and regulations with respect to all personally identifiable, confidential or regulated data in all material respects; and (vi)
the Company and its Subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements and no such disclosures have been in violation of any applicable laws or regulatory rules and requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Officer&#8217;s
Certificates</I>. Any certificate signed by any officer of the Company or any of its Subsidiaries, as the case may be, delivered
to the Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by the Company or any of
the Subsidiaries to each Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 2.&#9;<U>Sale
and Delivery to Underwriters; Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notes</I>.
On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the
Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees
to purchase from the Company, at the price set forth in Schedule C-1, the aggregate principal amount of Notes set forth in Schedule
A opposite the name of such Underwriter, plus any additional principal amount of Notes which such Underwriter may become obligated
to purchase pursuant to the provisions of Section 11 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Public
Offering</I>. The Company is advised by you that the Underwriters propose to make a public offering of their respective portions
of the Notes as soon after this Agreement has become effective as in your judgment is advisable. The Company is further advised
by you that the Notes are to be offered to the public upon the terms set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment</I>.
Payment of the purchase price for, and delivery of certificates for, the Notes shall be made at the offices of Shearman &amp; Sterling
LLP, 599 Lexington Avenue, New York, New York 10022, or at such other place as shall be agreed upon by the Representatives and
the Company at 9:00 A.M. (New York Time)&nbsp;on December 16, 2019 (unless postponed in accordance with the provisions of Section
11), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the
Company (such time and date of payment and delivery being herein called the &#8220;Closing Time&#8221;).</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Payment shall
be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company against delivery
to the Representatives for the respective accounts of the Underwriters of certificates for the Notes to be purchased by them. It
is understood that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and
make payment of the purchase price for, the Notes which it has agreed to purchase. JPMorgan, Morgan Stanley and Wells Fargo, individually
and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the
Notes to be purchased by any Underwriter whose funds have not been received by the Closing Time, but such payment shall not relieve
such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Denominations;
Registration</I>. Certificates for the Notes shall be in such denominations and registered in the name of Cede &amp; Co., as nominee
of the Depositary, pursuant to the DTC Agreement. The certificates for the Notes will be made available for examination by the
Representatives in The City of New York not later than 9:00&nbsp;A.M. (New York Time) on the business day prior to the Closing
Time.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 3.&#9;<U>Covenants
of the Company</U>. The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus</I>. The Company, as promptly as possible, will deliver to each
Underwriter, without charge, as many copies of the Registration Statement (including exhibits thereto and documents incorporated
by reference) and will deliver to each Underwriter during the period mentioned in Section 3(e) or 3(f) below, as many copies of
the Time of Sale Prospectus, the Prospectus and any amendments and supplements thereto and any documents incorporated therein by
reference, in each case, as such Underwriter may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments
and Supplements</I>. The Company will, before amending or supplementing the Registration Statement, the Time of Sale Prospectus
or the Prospectus, furnish to you a copy of each such proposed amendment or supplement and not file any such proposed amendment
or supplement to which you reasonably object and file with the Commission within the applicable period specified in Rule 424(b)
under the 1933 Act any prospectus required to be filed pursuant to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Free
Writing Prospectus</I>. The Company will furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not use or refer to any proposed free writing prospectus to which you reasonably
object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Free
Writing Prospectus (Underwriter)</I>. The Company will not take any action that would result in an Underwriter or the Company being
required to file with the Commission pursuant to Rule 433(d) under the 1933 Act a free writing prospectus prepared by or on behalf
of the Underwriter that the Underwriter otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amend
or Supplement Time of Sale Prospectus</I>. If the Time of Sale Prospectus is being used to solicit offers to buy the Notes at a
time when the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light
of the circumstances, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus
conflicts with the information contained in the Registration Statement then on file, or if, in the opinion of counsel for the Underwriters
or counsel to the Company, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the
Company will forthwith prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer
upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus
as so amended or supplemented will not, in the light of the circumstances when delivered to a prospective purchaser, be misleading
or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration Statement, or
so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amend
or Supplement Prospectus</I>. If, during such period after the first date of the public offering of the Notes, in the opinion of
counsel for the Underwriters or counsel to the Company, the Prospectus (or in lieu thereof the notice referred to in Rule 173(a)
under the 1933 Act) is required by law to be delivered in connection with sales by an Underwriter or dealer, any event shall occur
or condition exist as a result of which it is necessary to amend or supplement the Prospectus in order to make the statements therein,
in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the 1933
Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Underwriters or counsel to the Company,
it is necessary to amend or supplement the Prospectus to comply with applicable law, the Company will forthwith prepare, file with
the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses you will furnish
to the Company) to which Notes may have been sold by you on behalf of the Underwriters and to any other dealers upon request, either
amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not, in
the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the 1933 Act)
is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue
Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the Underwriters, to qualify the
Notes for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as
the Representatives may designate and to maintain such qualifications in effect as long as required for the sale of the Notes;
<I>provided</I>, <I>however</I>, that (i) the Company shall in no event be required to continue in effect any such qualification
for a period of more than 180 days after the Closing Time, (ii) the Company will not be required to qualify as a foreign corporation
or to file a general consent to service of process in any jurisdiction in which they are not so qualified and (iii) the Company
will not be required to subject itself to taxation (other than any nominal amount) in any jurisdiction if not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Rule
158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to their securityholders as soon as practicable an earnings statement for the purposes of, and to provide the benefits contemplated
by, the last paragraph of Section 11(a) of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Use
of Proceeds</I>. The Company will use the net proceeds received by them from the sale of the Notes in the manner specified in the
Time of Sale Prospectus and the Prospectus under &#8220;Use of Proceeds&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Restriction
on Sale of Notes</I>. Except as otherwise contemplated in the Time of Sale Prospectus and the Prospectus, during the period commencing
on the date hereof and ending at the Closing Time, the Company will not, without the prior written consent of the Underwriters,
(i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any debt securities or
guarantees of debt securities of the Company or any securities convertible into or exercisable or exchangeable for any debt securities
or guarantees of debt securities of the Company or file any registration statement under the 1933 Act with respect to any of the
foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of any debt securities or guarantees of debt securities of the Company, whether
any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any debt securities or guarantees
of debt securities of the Company or such other securities, in cash or otherwise. The foregoing sentence shall not apply to the
Notes to be sold hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Final
Term Sheet</I>. The Company will prepare a final term sheet relating to the offering of the Notes, containing only information
that describes the final terms of the Notes or the offering in a form consented to by the Representatives, and will file such final
term sheet within the period required by Rule 433(d)(5)(ii) under the 1933 Act following the date the final terms have been established
for the offering of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reporting
Requirements</I>. The Company, during the period when the Time of Sale Prospectus or the Prospectus is required to be delivered,
will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the
1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>DTC
Clearance</I>. The Company will use all reasonable efforts in cooperation with the Underwriters to permit the Notes to be eligible
for clearance and settlement through The Depository Trust Company.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 4.&#9;<U>Payment
of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Expenses</I>.
The Company will pay all expenses incident to the performance of its obligations under this Agreement, including (i)&nbsp;the preparation,
filing and printing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, any
free writing prospectus prepared by or on behalf of, used by, or referred to by the Company (including financial statements and
any schedules or exhibits)&nbsp;and of each amendment or supplement thereto, including the filing fees payable to the Commission
relating to the Notes (within the time required by Rule 456(b)(1), if applicable), and the delivery to the Underwriters of copies
of each, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of this Agreement, the DTC Agreement, the Indenture
and such other documents as may be required in connection with the offering, purchase, sale and delivery of the Notes, (iii)&nbsp;the
preparation, issuance and delivery of the certificates for the Notes to the Underwriters, (iv)&nbsp;the fees and disbursements
of the Company&#8217;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Notes under securities laws in
accordance with the provisions of Section 3(g)&nbsp;hereof, including filing fees and the reasonable fees and disbursements of
counsel for the Underwriters in connection therewith and in connection with the preparation of any Blue Sky Survey and any supplement
thereto, (vi)&nbsp;the fees and expenses of the Trustee, including the fees and disbursements of counsel for the Trustee in connection
with the Indenture and the Notes, (vii)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel
to the Underwriters in connection with, the review by The Financial Industry Regulatory Authority, Inc. (the &#8220;FINRA&#8221;)
of the terms of the sale of the Notes, if any, (viii) any fees payable in connection with the rating of the Notes and (ix) the
preparation, printing and delivery to the Underwriters of copies of any Blue Sky Survey and any supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination
of Agreement</I>. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 5 or Section
10(a)(i), 10(a)(ii)&nbsp;or Section 12&nbsp;hereof, the Company shall reimburse the Underwriters for all of their out-of-pocket
expenses, including the reasonable fees and disbursements of counsel for the Underwriters.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 5.&#9;<U>Conditions
of Underwriters&#8217; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the accuracy of the
representations and warranties of the Company contained in Section 1(a) hereof or in certificates of any officer of the Company
delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder
and to the following further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Counsel for the Company</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated as of
the Closing Time, of Shearman &amp; Sterling LLP, counsel for the Company, in form and substance reasonably satisfactory to counsel
for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in substantially
the form set forth in Exhibit A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Deputy General Counsel of the Company</I>. At the Closing Time, the Representatives shall have received the favorable opinion,
dated as of the Closing Time, of William J. O&#8217;Shaughnessy, Deputy General Counsel of the Company, in form and substance reasonably
satisfactory to counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters
in substantially the form set forth in Exhibit B hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
of Counsel for the Underwriters</I>. At the Closing Time, the Representatives shall have received the favorable opinion, dated
as of the Closing Time, of Fried, Frank, Harris, Shriver &amp; Jacobson LLP, counsel for the Underwriters, together with signed
or reproduced copies of such letter for each of the other Underwriters. In giving such opinion such counsel may rely, as to all
matters governed by the laws of jurisdictions other than the law of the State of New York and the federal law of the United States
and the General Corporation Law of the State of Delaware, upon the opinions of counsel satisfactory to the Representatives. Such
counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper,
upon certificates of officers of the Company and the Subsidiaries and certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Officers&#8217;
Certificate</I>. At the Closing Time, (i)&nbsp;the Prospectus, as it may then be amended or supplemented, including the documents
incorporated by reference therein, shall not contain an untrue statement of a material fact or omit to state a material fact necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading; (ii)&nbsp;there shall
not have been, since the respective dates as of which information is given in the Time of Sale Prospectus, any Material Adverse
Effect; (iii)&nbsp;the Company shall have complied with all agreements and satisfied all conditions on its part to be performed
or satisfied at or prior to the Closing Time; and (iv)&nbsp;the representations and warranties of the Company in Section&nbsp;1(a)
shall be accurate and true and correct as though expressly made at and as of the Closing Time. The Representatives shall have received
a certificate of Mark J. Guinan, Executive Vice President and Chief Financial Officer of the Company, and Sandip Patel, Vice President
&amp; Treasurer of the Company, dated as of the Closing Time, to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Prospectus,
Final Term Sheet and Free Writing Prospectus</I>. The Prospectus shall have been filed with the Commission pursuant to Rule 424(b)
under the 1933 Act within the applicable time period prescribed for such filing by the rules and regulations under the 1933 Act;
the final term sheet substantially in the form of Schedule C-2 hereto, and any material required to be filed by the Company pursuant
to Rule 433(d) under the 1933 Act, shall have been filed with the Commission within the applicable time periods prescribed for
such filings by Rule 433; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have
been issued and no proceeding for that purpose shall have been initiated or, to the Company&#8217;s knowledge, threatened by the
Commission and no notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment
thereto pursuant to Rule 401(g)(2) under the 1933 Act shall have been received; no stop order suspending or preventing the use
of the Prospectus or any issuer free writing prospectus shall have been initiated or threatened by the Commission; and all requests
for additional information on the part of the Commission shall have been complied with to the Representatives&#8217; reasonable
satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort
Letters</I>. At each of the times of the execution of this Agreement and the Closing Time, the Representatives shall have received
from PricewaterhouseCoopers LLP letters with respect to the Company dated the date hereof or the Closing Time, as the case may
be, in form and substance satisfactory to the Representatives or to counsel for the Underwriters and to PricewaterhouseCoopers
LLP, together with signed or reproduced copies of such letter for each of the other Underwriters, containing statements and information
of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to Underwriters with respect to the financial
statements and certain financial information of the Company contained in the Registration Statement, the Time of Sale Prospectus
and the Prospectus; <I>provided</I> that the letter delivered at the Closing Time shall use a &#8220;cut-off date&#8221; no more
than three business days prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Maintenance
of Rating</I>. At the Closing Time, the Notes shall be rated at investment grade by Moody&#8217;s Investors Service, Inc., S&amp;P
Global Ratings and Fitch Ratings, Inc. and the Company shall have delivered to the Representatives a letter dated the Closing Time,
from each such rating agency, or other evidence satisfactory to the Representatives, confirming that the Notes have such ratings;
and since the date of this Agreement, there shall not have occurred a downgrading in, or withdrawal of, the rating assigned to
the Notes or any of the Company&#8217;s other debt securities or debt instruments by any &#8220;nationally recognized statistical
rating organization&#8221; (as that term is defined under Section 3(a)(62) of the 1934 Act), and no such organization shall have
publicly announced that it has under surveillance or review its rating of the Notes or any of the Company&#8217;s other debt securities
or debt instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Twentieth
Supplemental Indenture</I>. At or prior to the Closing Time, the Company and the Trustee shall have executed and delivered the
Twentieth Supplemental Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional
Documents</I>. At the Closing Time, counsel for the Underwriters shall have been furnished with such documents and opinions as
they may reasonably require (including any consents under any agreements to which the Company is a party) for the purpose of enabling
them to pass upon the issuance and sale of the Notes as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the
Company in connection with the issuance and sale of the Notes as herein contemplated shall be satisfactory in form and substance
to the Representatives and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination
of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled,
this Agreement may be terminated by the Representatives by notice to the Company at any time at or prior to the Closing Time, and
such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections
1, 7, 8 and 9 shall survive any such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 6.&#9;<U>Covenants
of the Underwriters</U>. Each Underwriter severally covenants with the Company not to take any action that would result in the
Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 7.&#9;<U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of the Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, the directors and officers of each
Underwriter, and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act to the extent and in the manner set forth in clauses (i), (ii) and (iii) below, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement or amendment thereof, any preliminary prospectus, the
Time of Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the 1933 Act, any Company information
that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or the Prospectus or any amendment
or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary
in order to make the statements therein, (and other than with respect to the Registration Statement, in light of the circumstances
in which they were made) not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <I>provided</I>
that (subject to Section 7(d)&nbsp;below)&nbsp;any such settlement is effected with the written consent of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representatives), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental
agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission, to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><I>provided</I>, <I>however</I>,
that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any
untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information
furnished to the Company by any Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors
and officers, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20
of the 1934 Act against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection&nbsp;(a)
of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions,
made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus
or the Prospectus or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished
to the Company by such Underwriter through the Representatives expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a
result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 7(a) above, counsel to such indemnified parties shall be selected
by the Representatives, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to such indemnified parties
shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; <I>provided</I>,
<I>however</I>, that counsel to the indemnifying party shall not (except with the consent of the indemnified party)&nbsp;also be
counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel
(in addition to any local counsel)&nbsp;separate from their own counsel for all indemnified parties in connection with any one
action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances.
No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the
entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 7
or Section 8 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise
or consent (i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation,
investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a
failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 7(a)(ii)&nbsp;effected without its written consent if (i)&nbsp;such settlement
is entered into more than 60 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying
party shall have received notice of the terms of such settlement at least 45 days prior to such settlement being entered into and
(iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party for the indemnified party&#8217;s reasonable
fees and expenses of counsel in accordance with such request prior to the date of such settlement. Notwithstanding the immediately
preceding sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for fees and expenses of counsel, an indemnifying party shall not be liable for any settlement effected without its consent
if such indemnifying party (A) reimburses such indemnified party in accordance with such request to the extent it considers such
request to be reasonable and (B) provides written notice to the indemnified party disputing the unpaid balance in good faith and
substantiating the unpaid balance as unreasonable, in each case prior to the date of such settlement, subject to provision of notice
by the indemnified party in accordance with (i) and (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 8.&#9;<U>Contribution</U>.
If the indemnification provided for in Section&nbsp;7 hereof is for any reason unavailable to or insufficient to hold harmless
an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified
party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other hand from the offering of the Notes pursuant to this Agreement or (ii)&nbsp;if the allocation
provided by clause&nbsp;(i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause&nbsp;(i)&nbsp;above but also the relative fault of the Company on the one hand and of the
Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims,
damages or expenses, as well as any other relevant equitable considerations.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The relative
benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the
Notes pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering
of the Notes pursuant to this Agreement (before deducting expenses)&nbsp;received by the Company and the total discount received
by the Underwriters, in each case as set forth on the cover of the Prospectus bear to the aggregate initial offering prices of
the Notes as set forth on such cover of the Prospectus.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The relative
fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters, and the parties&#8217; relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Company
and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;8 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose)&nbsp;or by any other method of allocation
which does not take account of the equitable considerations referred to above in this Section 8. The aggregate amount of losses,
liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 8 shall be deemed
to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against
any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
based upon any such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Notwithstanding
the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount in excess of the amount by which
the total price at which the Notes sold by it exceeds the amount of any damages which such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">No person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the 1933 Act)&nbsp;shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">For purposes
of this Section&nbsp;8, (a) each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or
Section 20 of the 1934 Act shall have the same rights to contribution as such Underwriter and (b) each director of the Company
and each person, if any, who controls the Company, as the case may be, within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters&#8217; respective obligations to
contribute pursuant to this Section 8 are several in proportion to the principal amount of Notes set forth opposite their respective
names in Schedule&nbsp;A hereto and not joint.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 9.&#9;<U>Representations,
Warranties and Agreements to Survive Delivery</U>. All representations, warranties and agreements contained in this Agreement or
in certificates of officers of the Company or any of the Subsidiaries submitted pursuant hereto shall remain operative and in full
force and effect, regardless of any investigation made by or on behalf of any Underwriter or controlling person, or by or on behalf
of the Company, and shall survive delivery of the Notes to the Underwriters.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 10.&#9;<U>Termination
of Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination;
General</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing
Time (i)&nbsp;if there has been, since the time of execution of this Agreement or since the respective dates as of which information
is given in the Time of Sale Prospectus, any material adverse change in the condition (financial or otherwise), earnings, business
affairs or business prospects of the Company and the Subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business, (ii)&nbsp;if there shall have occurred a downgrading in the rating of the Company&#8217;s debt securities by
any nationally recognized statistical rating organization, or if such rating organization shall have publicly announced that it
has under surveillance or review, with possible negative implications, its rating of the Company&#8217;s debt securities, (iii)
if there has occurred any material adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a
prospective change in national or international political, financial or economic conditions, in each case the effect of which is
such as to make it, in the judgment of the Representatives, impracticable to market the Notes or to enforce contracts for the sale
of the Notes, (iv)&nbsp;if trading in any securities of the Company has been suspended or limited by the Commission or the New
York Stock Exchange, or if trading generally on the New York Stock Exchange or on the NASDAQ Global Select Market has been suspended
or limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of
said exchanges or by such system or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;if a banking
moratorium has been declared by either federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Liabilities</I>.
If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other
party except as provided in Section 4 hereof, and provided further that Sections 1, 7, 8 and 9 shall survive such termination and
remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 11.&#9;<U>Default
by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the Closing Time to purchase the Notes
which it or they are obligated to purchase under this Agreement (the &#8220;Defaulted Notes&#8221;), the Representatives shall
have the right, but not the obligation, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting
Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Notes in such amounts as may
be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements
within such 24-hour period, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
the number of Defaulted Notes does not exceed 10% of the aggregate principal amount of the Notes to be purchased hereunder, each
of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions
that their respective obligations hereunder bear to the obligations of all non-defaulting Underwriters, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
the number of Defaulted Notes exceeds 10% of the aggregate principal amount of the Notes to be purchased hereunder, this Agreement
shall terminate without liability on the part of any non-defaulting Underwriters.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">No action taken
pursuant to this Section shall relieve any defaulting Underwriters from liability in respect of its default.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In the event
of any such default which does not result in a termination of this Agreement, either (i) the Representatives or (ii) the Company
shall have the right to postpone the Closing Time for a period not exceeding seven days in order to effect any required changes
in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements. As
used herein, the term &#8220;Underwriters&#8221; includes any person substituted for an Underwriter under this Section 11.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 12.&#9;<U>Default
by the Company</U>. If the Company shall fail at the Closing Time to sell the number of Notes that they are obligated to sell hereunder,
then this Agreement shall terminate without any liability on the part of any non-defaulting party; <I>provided</I>, <I>however</I>,
that the provisions of Sections 1, 4, 7, 8 and 9 shall remain in full force and effect. No action taken pursuant to this Section
shall relieve the Company from liability, if any, in respect of such default.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 13.&#9;<U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
by any standard form of telecommunication. Notices to the Underwriters shall be directed to J.P. Morgan Securities LLC, 383 Madison
Ave., 6th Floor, New York, NY 10179, attention of Investment Grade Syndicate Desk, with a copy to Fried, Frank, Harris, Shriver
&amp; Jacobson LLP, One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; Morgan Stanley &amp; Co. LLC,
1585 Broadway, 29<SUP>th</SUP> Floor, New York, NY 10036, attention of Investment Banking Division, with a copy to Fried, Frank,
Harris, Shriver &amp; Jacobson LLP, One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; Wells Fargo
Securities, LLC, 550 South Tryon Street, Charlotte, NC 28202, attention of Transaction Management, with a copy to Fried, Frank,
Harris, Shriver &amp; Jacobson LLP, One New York Plaza, New York, New York 10004, attention of Mark S. Hayek, Esq.; and notices
to the Company shall be directed to it at 500 Plaza Drive, Secaucus, NJ 07094 attention of Deputy General Counsel and Corporate
Secretary, with a copy to Shearman &amp; Sterling LLP, 599 Lexington Avenue, New York, New York 10022, attention of Lona Nallengara,
Esq.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 14.&#9;<U>Parties</U>.
This Agreement shall inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors.
Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other
than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred
to in Sections&nbsp;7 and 8 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in
respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended
to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling
persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation.
No purchaser of the Notes from any of the Underwriters shall be deemed to be a successor by reason merely of such purchase.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 15.&#9;<U>Governing
Law and Time</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT
REGARD TO CONFLICTS OF LAW PRINCIPLES THEREOF. SPECIFIED TIMES OF DAY HEREIN REFER TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 16.&#9;<U>Effect
of Headings</U>. The Article, Section and subsection headings herein and the Table of Contents are for convenience only and shall
not affect the construction hereof.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 17.&#9;<U>Partial
Unenforceability</U>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this
Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 18.&#9;<U>No
Advisory or Fiduciary Responsibility</U><I>.</I> The Company acknowledges and agrees that: (i) the purchase and sale of the Notes
pursuant to this Agreement, including the determination of the offering price of the Notes and any related discounts and commissions,
is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other
hand, and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of
the transactions contemplated by this Agreement; (ii) in connection with each transaction contemplated hereby and the process leading
to such transaction each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company
or its affiliates, stockholders, creditors or employees or any other party; (iii) no Underwriter has assumed or will assume an
advisory or fiduciary responsibility in favor of the Company with respect to any of the transactions contemplated hereby or the
process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters)
or any other obligation to the Company except the obligations expressly set forth in this Agreement; (iv) the several Underwriters
and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
the Company and that the several Underwriters have no obligation to disclose any of such interests by virtue of any fiduciary or
advisory relationship;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">and (v) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect
to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the
extent it deemed appropriate. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the
Company may have against the several Underwriters with respect to any breach or alleged breach of fiduciary duty.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 19.&#9;<U>Recognition
of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective
to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime
if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">As used in
this Section 19:</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&#8220;BHC
Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with,
12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&#8220;Covered
Entity&#8221; means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;a
&#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
&#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: (normal text),serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;a
&#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&#8220;Default
Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&#8220;U.S.
Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">SECTION 20.&#9;<U>General
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>General</I>.
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all
contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may
be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument. <FONT STYLE="background-color: white">Any signature delivered by a party hereto via facsimile,
electronic&nbsp;mail in &#8220;portable document format&#8221; (.pdf) form or any other electronic&nbsp;transmission shall be deemed
to be an original signature hereto. </FONT>This Agreement may not be amended or modified unless in writing by all of the parties
hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is
meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction
or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>USA
Patriot Act.</I> In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October
26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including
the Company, which information may include the name and address of their respective clients, as well as other information that
will allow the Underwriters to properly identify their respective clients.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp; - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">If the foregoing
is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon
this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Very Truly Yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">QUEST DIAGNOSTICS INCORPORATED</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Sandip Patel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Vice President &amp; Treasurer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Signature Page to Quest Diagnostics Incorporated
Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">&nbsp; </TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">CONFIRMED AND ACCEPTED, <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of the date first above written:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">J.P. MORGAN SECURITIES LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MORGAN STANLEY &amp; CO. LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">WELLS FARGO SECURITIES, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: J.P. MORGAN SECURITIES LLC<FONT STYLE="text-transform: uppercase"><BR>
<BR>
<BR>
</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">By</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Robert Bottamedi</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">Robert Bottamedi</TD>
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Executive Director</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: MORGAN STANLEY &amp; CO. LLC<FONT STYLE="text-transform: uppercase"><BR>
<BR>
<BR>
<BR>
</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>By</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Ian Drewe</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">Ian Drewe</TD>
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Executive Director</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: WELLS FARGO SECURITIES, LLC<FONT STYLE="text-transform: uppercase"><BR>
<BR>
<BR>
<BR>
</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>By</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Carolyn Hurley</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">Carolyn Hurley</TD>
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">For themselves and the other Underwriters<BR>
named in Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">[<I>Signature Page to Quest Diagnostics
Incorporated Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.5in; text-align: center"><U>SCHEDULE A &#8211; <FONT STYLE="text-transform: uppercase">Underwriters</FONT></U></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><B>Name of Underwriter</B></TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><B>Principal Amount<BR>
of Notes To Be Purchased</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">J.P. Morgan Securities LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$176,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Morgan Stanley &amp; Co. LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$176,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Wells Fargo Securities, LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$176,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Goldman Sachs &amp; Co. LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$72,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Mizuho Securities USA LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$72,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Credit Agricole Securities (USA) Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$32,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">MUFG Securities Americas Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$28,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Fifth Third Securities, Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$18,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">PNC Capital Markets LLC</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$18,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">BofA Securities, Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$16,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">KeyBanc Capital Markets Inc.</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">$16,000,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-indent: 22.5pt">Total:</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: -0.9pt; padding-bottom: 6pt; text-align: right">$800,000,000&nbsp;&nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 29.85pt 12pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 29.85pt 12pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 29.85pt 12pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 29.85pt 12pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE B &#8211; TIME OF SALE PROSPECTUS</U></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Prospectus dated June 14, 2019 relating to the Shelf Securities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Preliminary prospectus supplement dated December 9, 2019 relating to the Notes.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Final Term Sheet for the Notes.</TD></TR></TABLE>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>SCHEDULE C-1 &#8211; PURCHASE PRICE</U></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The purchase
price for the 2.950% Senior Notes due 2030 is 99.088%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-1</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>SCHEDULE C-2 &#8211; FINAL TERM SHEET</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>FINAL TERM SHEET</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><I>Dated December 9, 2019</I></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>$800,000,000</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Quest Diagnostics Incorporated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>$800,000,000 2.950% Senior Notes due
2030</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Issuer:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">Quest Diagnostics Incorporated</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Trade Date:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">December 9, 2019</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Original Issue Date (Settlement):</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">December 16, 2019 (T+5)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Accrual Date:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">December 16, 2019</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Principal Amount:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">$800,000,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Maturity Date:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">June 30, 2030</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Issue Price (Price to Public):</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">99.738%&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Yield:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">2.979%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Rate:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">2.950% per annum</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Payment Period:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">Semi-annual</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Interest Payment Dates:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">Each June 30 and December 30, commencing June&nbsp;30,&nbsp;2020</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Treasury Benchmark:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">1.750% due November 15, 2029</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Spread to Benchmark:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">T+115 bps</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Benchmark Yield:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">1.829%</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Optional Redemption:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to March 30, 2030 (three months prior to their maturity date)
        (the &#8220;par call date&#8221;), the Notes will be redeemable, as a whole or in part, at the option of the Issuer, on at least
        15 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the Notes, at a redemption
        price equal to the greater of:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 13.5pt; text-indent: -9pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;&#9; </FONT>100%
        of principal amount of the Notes to be redeemed, and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 13.65pt; text-indent: -9.35pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;&#9; </FONT>the
        sum of the present values of the remaining scheduled payments through the par call date discounted, on a semiannual basis,
        assuming         a 360-day year consisting of twelve 30-day months, at the applicable treasury rate plus 20 basis points,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt">&nbsp;</TD>
    <TD STYLE="padding: 0.05in 5.75pt"><P>plus accrued interest to, but excluding, the date of redemption which has not been paid.</P>

<P>On or after the par call date, the Notes will be redeemable, as a whole at any time or in part from time to time, at
the option of the Issuer, at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus accrued
interest to, but excluding, the date of redemption which has not been paid.</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>CUSIP:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">74834L BB5</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>ISIN:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">US74834LBB53</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Joint Book-Running Managers:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">J.P. Morgan Securities LLC<BR>
Morgan Stanley &amp; Co. LLC<BR>
Wells Fargo Securities, LLC<BR>
Goldman Sachs &amp; Co. LLC<BR>
Mizuho Securities USA LLC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Co-Managers:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Credit Agricole Securities (USA) Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MUFG Securities Americas Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fifth Third Securities, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PNC Capital Markets LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">BofA Securities, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">KeyBanc Capital Markets Inc.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Conflicts of Interest:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">The Issuer intends to use the net proceeds of the offering to repay at maturity or redeem its 4.75% Senior Notes due 2020 and 2.50% Senior Notes due 2020 pursuant to the applicable provisions of the indenture governing these notes. Certain of the underwriters (or their affiliates) may hold and would receive a portion of the proceeds from this offering if such notes were to be redeemed. If any one underwriter, together with its affiliates, were to receive 5% or more of the net proceeds of this offering by reason of the redemption, such underwriters would be deemed to have a &#8220;conflict of interest&#8221; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (&#8220;Rule 5121&#8221;). Accordingly, this offering will be conducted in accordance with Rule 5121. No underwriter with a &#8220;conflict of interest&#8221; under Rule 5121 will confirm sales to any account over which it exercises discretion without the specific written approval of the account holder.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.05in 5.75pt"><B>Global Settlement:</B></TD>
    <TD STYLE="padding: 0.05in 5.75pt">Through The Depository Trust Company, Euroclear or Clearstream, Luxembourg.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><I>The issuer expects that delivery of the notes will be
made on or about the Original Issue Date (Settlement), which is five business days following the pricing of the notes (this settlement
cycle being referred to as &#8220;T+5&#8221;). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally
are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers
who wish to trade notes on the date of pricing will be required, by virtue of the fact that the notes will settle in T+5, to specify
an alternative settlement cycle at the time of any such trade to prevent a failed settlement; such purchasers should also consult
their own advisors in this regard.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><I>The Issuer has filed a registration statement (including
a prospectus and a prospectus supplement) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) for the offering
to which this communication relates. Before you invest, you should read the prospectus and the prospectus supplement in that registration
statement and other documents the Issuer has filed with the SEC for more complete information about the issuer and this offering.
You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Issuer, any underwriter
or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request
it by calling J.P. Morgan Securities LLC collect at 1-212-834-4533; Morgan Stanley &amp; Co. LLC toll-free at 1-866-718-1649;
and Wells Fargo Securities, LLC toll free at 1-800-645-3751.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>SCHEDULE D &#8211; SUBSIDIARIES</U></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Holdings Incorporated (DE)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics International Holdings Limited (UK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 5%; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 24%; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt; width: 71%"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Holdings Ltd. (UK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Exam<I>One</I>&nbsp;Canada, Inc. (New Brunswick)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Brasil Holdings Ltd. (UK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 44pt"><FONT STYLE="font-size: 10pt">65% Quest Diagnostics Testes Forenses do Brasil Ltda. (Brazil)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">99.9% Quest Diagnostics HTAS India Private Limited (India) (0.1% Quest Diagnostics International Holdings Limited (UK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics of Puerto Rico, Inc. (PR)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Ireland Limited (Ireland)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics (Shanghai) Co., Ltd. (China)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Subsidiary Holdings Ltd. (UK)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 44pt; text-align: justify"><FONT STYLE="font-size: 10pt">40% Q Squared Solutions Holdings Limited (UK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics do Brasil Ltda. (Brazil)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Clinical Laboratories, Inc. (DE)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Lab<I>One</I>, LLC (MO)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Exam<I>One</I>&nbsp;World Wide, Inc. (PA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% ExamOne LLC (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% ExamOne World Wide of NJ, Inc. (NJ)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;51% DGXWMT JV, LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Mobile Medical Examination Services, LLC (CA)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Health &amp; Wellness LLC (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Lab<I>One</I>&nbsp;of Ohio, Inc. (DE)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">44% Mid America Clinical Laboratories (IN)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">51% Diagnostic Laboratory of Oklahoma LLC (OK)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">49% Sonora Quest Laboratories LLC (AZ)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">70% Quest Diagnostics Domestic Holder LLC (DE) </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0pt 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">40% Q Squared Solutions Holdings, LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Incorporated (MD)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Diagnostic Reference Services Inc. (MD)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt 0pt 22pt"><FONT STYLE="font-size: 10pt">100% Pathology Building Partnership (MD) (gen. ptnrshp.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Incorporated (MI)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics India Private Limited (India)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Infectious Disease, Inc. (DE)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0pt 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">(30%)&nbsp; Quest Diagnostics Domestic Holder LLC (DE) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics International LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0pt 1.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics LLC (MA)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">81.1% Quest Diagnostics Massachusetts LLC (MA)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics LLC (CT)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Mexico Holding Company Trust (Mexico)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Mexico, S de RL de CV (Mexico)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Terracotta LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Nichols Institute (CA)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics of Pennsylvania Inc. (DE)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">51% Quest Diagnostics Venture LLC (PA)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">53.5% Associated Clinical Laboratories of Pennsylvania, L.L.C. (PA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">1% Associated Clinical Laboratories, L.P. (PA)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">52.97% Associated Clinical Laboratories, L.P. (PA)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Receivables Inc. (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics TB, LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100 % Quest Diagnostics Ventures LLC (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Athena Diagnostics, Inc. (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% American Medical Laboratories, Incorporated (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Nichols Institute, Inc. (VA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Quest Diagnostics Incorporated (NV)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Clearpoint Diagnostic Laboratories, LLC (TX)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Cleveland HeartLab, Inc. (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Isabella Street Urban Renewal, LLC (NJ)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Med Fusion, LLC (TX)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Nomad Massachusetts, Inc. (MA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Laboratorio de Analisis Biomedicos, S.A. (Mexico)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Reprosource Fertility Diagnostics, Inc. (MA)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Unilab Corporation (DE)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="8" STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% AmeriPath, Inc. (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Cincinnati, Inc. (OH)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Cleveland, Inc. (OH)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Consolidated Labs, Inc. (FL)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Florida, LLC (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Hospital Services Florida, LLC (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Kentucky, Inc. (KY)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Lubbock 5.01(a) Corporation (TX)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath New York, LLC (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Texas Inc. (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% AmeriPath Tucson, Inc. (AZ)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Arlington Pathology Association 5.01(a) Corporation (TX)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Consolidated DermPath, Inc. (DE)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% DFW 5.01(a) Corporation (TX)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Diagnostic Pathology Services, Inc. (OK)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Kailash B. Sharma, M.D., Inc. (GA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top; padding: 1.5pt"><FONT STYLE="font-size: 10pt">100% Nuclear Medicine and Pathology Associates (GA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Institute for Dermatopathology, Inc. (PA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Ocmulgee Medical Pathology Association, Inc. (GA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% Specialty Laboratories, Inc. (CA)</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: top; padding: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">100% TXAR 5.01(a) Corporation (TX)</FONT></TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->D-2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 87%; padding: 1.5pt"><FONT STYLE="font-size: 10pt">A. Bernard Ackerman, M.D. Dermatopathology, PC (NY)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">AmeriPath Indianapolis, P.C. (IN)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">AmeriPath Milwaukee, S.C. (WI)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Colorado Pathology Consultants, P.C. (CO)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Dermatopathology of Wisconsin, S.C. (WI)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Diamond Occupational Health Services, P.S.C. (PR)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Hoffman, M.D., Associated Pathologists Chartered (NV)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Kilpatrick Pathology, P.A. (NC)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">PhenoPath Laboratories, PLLC (WA)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">D-3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ss159854_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Quest Diagnostics Prices $800 Million of Senior Notes<BR>
</B><FONT STYLE="font-weight: normal">December 9, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 12pt; margin-left: 0">SECAUCUS, N.J., <FONT STYLE="font-weight: normal">Dec.
9, 2019  </FONT>-- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information
services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes
due 2030 under the Quest Diagnostics&rsquo; shelf registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 12pt; margin-left: 0">Quest Diagnostics expects
to receive the net offering proceeds upon closing on December 16, 2019, subject to customary closing conditions. The company intends
to use the net proceeds from the offering to repay at maturity or redeem its 4.750% senior notes due 2020 and 2.500% senior notes
due 2020 and for general corporate purposes. This press release is not a notice of redemption. Any notice of redemption will be
made in accordance with the applicable provisions of the indenture governing such notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 12pt; margin-left: 0">This press release shall
not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer,
solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering
may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning
this offering may be obtained by calling J.P. Morgan Securities LLC, collect at (212) 834-4533, Morgan Stanley &amp; Co. LLC, toll-free
at (866) 718-1649 or Wells Fargo Securities, LLC, toll-free at (800) 645-3751.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><B>About Quest Diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Quest Diagnostics empowers people to take action to improve health
outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify
and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three
adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right
hands and with the right context, our diagnostic insights can inspire actions that transform lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The statements in this press release which are not historical facts
may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak
only as of the date that they are made and which reflect management&rsquo;s current estimates, projections, expectations or beliefs
and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties
that may affect the future results of the company include, but are not limited to, adverse results from pending or future government
investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue
recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers,
suppliers or strategic partners and other factors discussed in the company&rsquo;s most recently filed Annual Report on Form 10-K
and in any of the company&rsquo;s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including
those discussed in the &ldquo;Business,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Cautionary Factors that May Affect Future Results&rdquo;
and &ldquo;Management's Discussion and Analysis of Financial Condition and Results of Operations&rdquo; sections of those reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CONTACT: Denny Moynihan, Quest Diagnostics (Media): 973-520-2800;
Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dgx-20191209.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qs5w7xRiXgOn8uGaH9cOaiImaPtzJJ9aZkhsmd1bUlqvyAmwi22dSlhg4FGAdAO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:DGX="http://DGX/20191209" elementFormDefault="qualified" targetNamespace="http://DGX/20191209">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://DGX/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="dgx-20191209_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="dgx-20191209_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dgx-20191209_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dgx-20191209_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://DGX/role/Cover" xlink:href="dgx-20191209.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://DGX/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6616569904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 09, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  09,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Quest Diagnostics Incorporated<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001022079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1387862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Plaza Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Secaucus<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">520-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DGX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>10
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ss159854_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ss159854_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dgx-20191209_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dgx-20191209_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dgx-20191209.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "DGX",
   "nsuri": "http://DGX/20191209",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ss159854_8k.htm",
      "contextRef": "From2019-12-09to2019-12-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://DGX/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ss159854_8k.htm",
      "contextRef": "From2019-12-09to2019-12-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://DGX/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ss159854_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://DGX/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ss159854_8k.htm">ss159854_8k.htm</File>
    <File>dgx-20191209.xsd</File>
    <File>dgx-20191209_lab.xml</File>
    <File>dgx-20191209_pre.xml</File>
    <File>ss159854_ex0101.htm</File>
    <File>ss159854_ex9901.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MT>% "7C-@<EY8CA.?0<7P PCC"Y]%] LQ%+]$ULZP$[)*=DE-8YC/:Y*+N_
MX>WI\:6L6]DAD1HTYE?)"CH&W+#SY-?5W?WV@<FVX>N*M_EL^:W@C;A>O\^N
M/_PNPLX;N[/_V/@L*#OX]2_D%U!+ P04    " !AB8Q/F5R<(Q &  "<)P
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M\)03&&+JFX]A0N[C42<PR12XCV!"[N-Y)S#.%+@/,5G(?3SS!"8Z ^Y#3.C
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MC.\?1H]BZ<&8A6#O[I5TXH\<P_?,?P!02P,$%     @ 88F,3__ )@B]
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MUO]H=)G+H%W\S<A'2NU!7PW_R?(+4$L! A0#%     @ 88F,3Q\CSP/
M$P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%     @
M88F,3R?HAPZ"    L0   !               ( !Z0   &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !AB8Q/OTT' NX    K @  $0
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M2P$"% ,4    " !AB8Q/NJ$YBM<!   R!@  #0              @ %%#@
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &&)C$\P _>^-P$  "("   /
M          "  4<0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !AB8Q/
M_\ F"+T   "% @  &@              @ &K$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " !AB8Q/"X_8 R$!  !7!   $P
M        @ &@$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "@ * ( "
(  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>ss159854_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dgx-20191209.xsd" xlink:type="simple"/>
    <context id="From2019-12-09to2019-12-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001022079</identifier>
        </entity>
        <period>
            <startDate>2019-12-09</startDate>
            <endDate>2019-12-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-12-09to2019-12-09">0001022079</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-12-09to2019-12-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2019-12-09to2019-12-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2019-12-09to2019-12-09">2019-12-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2019-12-09to2019-12-09">Quest Diagnostics Incorporated</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-12-09to2019-12-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2019-12-09to2019-12-09">001-12215</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-12-09to2019-12-09">16-1387862</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-12-09to2019-12-09">500 Plaza Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2019-12-09to2019-12-09">Secaucus</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2019-12-09to2019-12-09">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2019-12-09to2019-12-09">07094</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-12-09to2019-12-09">(973)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-12-09to2019-12-09">520-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2019-12-09to2019-12-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2019-12-09to2019-12-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2019-12-09to2019-12-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2019-12-09to2019-12-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2019-12-09to2019-12-09">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-12-09to2019-12-09">DGX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-12-09to2019-12-09">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-12-09to2019-12-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000947871-19-000957-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000947871-19-000957-xbrl.zip
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MF)^/=V1L];_+D3ZVYVO3R23U\"]02P,$%     @ 88F,3[!B;4G\"@  WX<
M !0   !D9W@M,C Q.3$R,#E?;&%B+GAM;,V=76_CN!6&[POT/[#>FQ88QW&"
M+9#LS"XRGF1A;#9)8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2S$5&([Z'
M>BD^(:D/4A]_VFTH>B$B33C[-)H>'8\081&/$[;^-/JZ&%\L9O/Y"*499C&F
MG)%/(\9'/_WXYS\A^?/Q+^,QNDH(C<_1%QZ-Y^R!_X!N\(:<HY\)(P)G7/R
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MV43#$ 7$AMT9 $<I1KD:2;E'/.Y$LL%BOTBBGLZC+70+"&2T28BI"@@1P!K
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M)3\-VD,$_JA82M1JR.+J8>18"T6.DI6&#2(R'Y'E(+'>V(05,X[5Z+U%H!%
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MI]IT,,3LC\OA>*+T[W_*A]*1OX3@W\@2TG-K$ NTYU=11-(,B;T LFG2"@4
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M4@H /_Y.'85IK ,.K *+YN 2_ ><2(]7$"9?.L-1MGG;_/ZF"EKF9[UV9G-
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M?G^"L;6E^_LKJ<$G^C%6'NJ0MXQC788N-N5V=X;@$$2'NAL<PK1$%>XQ(L!
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M#/#=]KR3":J;_!>\]7DXP#]X'&1)M,SHJX89?44/O>A]^'SH[1]^_GS:.S@
MP?N?GS9_HK_/3WO[ZF^YI4S<((WC8)+#>-2_G)79\^S5V.3'G*E[7(=9$0V"
M6 D_C*_Q"+XX4%?(K7=V_F:6YN*@Z1<O_S9=MS1?5;WOSQ=G^!^<&%G^^N1.
M8&%>]+,P^/:B'X[2#-XTB&^"VUQ/\XQYKUMG[L9Q'FQ+WST*WA+NUCS_8!Q>
M!/TX]-*1MP_WAH_SI=F'C4]65NG7]SA?[W[^JI]%SUM(ZAVE@Q=K6:Z*[9Y7
ME6Y>=-X1\]KN[!(<M#^$/HF288CW?"'VS"08#J/DDN5N$^=#?:($S_D0[_0+
MVT*.]$]]/,WJG(^J[ZE[GCK0ZZ#'+[.T3(:HHM(,!GS97]O>?.EO[[SQMW=W
MUQNF5U;W[>;?ZFKH'J;Z_'"?7*2M#9X>^[\@K6?A) MS>!H9E;D7)$/OMR#+
M@J2(PISEN&F5M(S^K6$?S+UB.P^Z6+]=146XV@ _>@/<:7KM3Z9,[Q9.[EJP
MWB#K1S-DW>O?>L55".?%>!(DM^]^/FH1_9GKTS+69R7N"ZU'OWD]3D:C:!!F
M?_^O-]M;K_=R;Q]?&CX"CR&_C^G?>MCYOZ^ML=(\#ZW-U1F[W7S&G@=@B:*R
M.0CC"%X=]$SJ?87G9S<9C#D#&WX_3G.X;?MY>_>EV7JYDOJ5U/^P0Y8 PGO1
MWL]3CI=QD)Z6_3@:>'">PNA1BSR[V7\X,1^T3'EP.X9'/,.I?A2"/FR>]8,P
M2<=1PO;[GG<67D9YP?&09[@2*__TZ4CWW0S&G6:#<3^]#A/P2G/$+QV?]-F9
MARL9?SHRO@SS4+M (-FV^O;."W#[\4CE]\/OR6\ZS=)\$@Z*DO$:\^=*X=^_
M8=F#!1GBHO#DGY>324R+=#^SO[O:-BWFYL<L#+W?LJB W]_W'GC857BX/=!B
M<[9,O;=F(3CKSW A'L5V"*?H)2_-+(W4=FH\PY5YN"TRFG\YGO4*/(J]<=F\
M&!_B,O3.O]UZ_RSA\11.06_Y7E;AU5]T'URU!!A+4#U;NV^>X5P_"HF/FJ?]
M:TZ*'S3.( R'*TE?YI3_T19*!\<MXF1 =-X"SK6Z/_!_)?UKWUKLTR@)8N\B
MS,;>^548W@\D_5<5_[@UDR3-R"$X"_]=1MD]^L2O5X(_;H&2+O:]_3@,LB 9
MA,]P[E?0Z-.1Y[O!_R^;X7^)+>*!>OCG)$SR:8F8WX'\K\1[)=X_#ODWHKS2
MU/>-VZ,U*&%RU"*]RRP,[RU=X7E:*"N-\M!:6IV2NVU!\F08<2(WB+B=3BD)
MQ=Y)'\:GT*]G=WZN!/_I"/XRSL^3292(/M^'@>9A#.^7W7?)PC,5\J64+Y@%
M.0@G97'K?0J3, MBO3[5[)U[6)XW?]%-TA(GG[))[!/B&2[%H]@I+2%T*?31
M![-5Z/,,5^+A-D5+M-R$8GVOBA937L^/S"Y9[9*V*#H<$Z"K"N]S6-R;CGK[
M%]T9+;'R+T&$Y  ((%-"8H [X!E._*,0^Y:@^<5-B/6WQ965/0(JZH@>7&;W
M<T+\5?=!2P2]-V17&N;](!V4]Q?-<N==.$]:V>,,.\EL@KDI)#;;C20V>]Z_
M@KA$QI@[T]FT,/ML&V:?OP;=S0N',49-_)YW<3N!(7Y.;\*,=L:>=QR,0UZ@
MXQ2G/7*H9M25^(WW8OI8G@.)3KNH/UJ^F,=YNNC]\1:GH"UIY<>AXM9^_=OS
M.FU6Z. C E\50OYJSC(R%P*Y!T1\)>@K0;]/07_=+.CH*XP3G>M\'Z*]O;D2
M[95H_[!@3T6BFQ7X\OVSYR3ERPCQ-"R#!'-\[R#*P)%,,RZ-5!#W,UR51[%/
M6N(]O8%0N5T&49(7X%EFR.6VAYGHUGEP#VNR]1?=*2TAGO.P**3RZR8JKM*R
M0.)5)-OSHI'W,8CB,@N1]^HLC,;],LOO!==[X%5Y',;2LSVP'T$NTIO67*0B
MB_KEO5F?VRNY7LGU/<KUV[G8@7V;+A6M'@VAY:C:S\OL.KH.-<WAO>R$%8?G
M:B?<YT[8VFS>"NW@\4K(5T+^-&SW%K#!$NT]E<-X+];Y\Q3K90 -GZ.@'\41
M<^X_NYE?H9=/1YKO>&JVM)<X"$=!&1?(K7^2A$@1\R7-PA\5C]I^1G1N*[%_
MC&+?POANB?T]TW>N1'PEXO<KXBT<M0BP#^ZG,'TETRN9OE^9;B5>R*9WO?H.
MF7Y&E($KF7Z,,MU2)OTIA7=/X#+O<W!#H"V^UTK$5R+^]$2\)<_Q<#0*!T27
M\VL8X.4K#;X2[R<HWBW9C625!+'W-0F349H-0H8*[\>=7 GY2LCO5<A;,BB.
M4Z\WO([R%%M#9-[':%@.H@#^. OS29KDT4KF5S+_5&6^-;MBD%XFD9/@NW&^
MX9U/P@$J?!#]-*:<(FJ5,KXGS_09<;NNQ/\1BO]V2T:%8LLYS5)0_/?%TK7]
MC*@!5^+]> +Y+;D4]YD^\8PD>1DY$U_/>]YI4&116GB]P;UP6U:F7/,5F!+N
M^6=4%WO#_]W:=NO&W;+PN]V3!CP/'<+.BN_@X?@._MJ$!]\AV:T$";9<5>7.
MG4(C3'/JP#;QK+ L-(A@@YY4@T"A4LJ&M-$OWN[&RZ;S%K5$52/23\&V&ER%
M0^PVTVM6>?*PI3SKQ=1'O-E>QC/<3*#&4VZ^65[>S'YH?NW[FL[OOB_*;F/_
MLT<QF_LOMI[8?)Z6V> JR'$N(^PO\4BF<?N)36.]/<VCF,B#)S:-YV4_CX91
MD%%^PD-.X>&?5U$_*MI.GD<[@Q]3$$'0CQ9%+ ADD,'![_T]&(/5> ZG3TR1
M\L^GCV..G]H9U##'<U(C/Q4OB^\YCYOU<N5F/:";M?*S'L]^:5[=?WX]/+_P
M#HYZGXY/SB^.]L^]H^/]D[/3D[/>Q>'!NP^H"]8"+"8-;H(L!*'-)BDWBU]?
MRNB:A_7?;S8W_4W^_][VQMO=S;_!E:#-,NYNZ W+T-O>W-F\QS$L<0F>_@.F
M"M&[K^^_'A\<GOUV=G0!6L_K?3H[//QR>'S!H83E/'[[9?7Q=$#^]/X@'(3C
M?IAY;WT0"60_6\(#?WK_CXW3#>_+R=FGWK%W?KC_%=_M\!RLDOTE/4#=^Z)W
M_/GP=[%^]D\VEOB(W_ H\C[VSCZ=6._@+_$)K"$&/Z?>O<_7SIL=[TLPC'(P
M:7K7X8;OO7IW_O7T?7'U[F?\7^]CG*;9DAZ&O_D]S;[YWO'O<.W6ZV6)U1+W
MY$_O<=Y_@!AM[;[9]3YD:3"$TQ0VV=L?-N^;.Z\>Z[S?_][:W=WTSM.RN/(N
MLEOL[UMDY+HOY>;[5T$6@_43PDSO>]MOMC>W']],:W/H,^Q[8;L 'X8YCGZ9
M]HB?\;KO.]W^*/,B&MU6(FD2UOUG&>:%=Q %ETD*/QODW<Y1HHRC<.A[S3:3
MMX;^%G;@V-[<$[>+_MK:6X??):,H&^=>5""7EE ;$).3:-<TNP0_^3P<E!E5
M*:.P>6MRNW^<\O?J?GZWHRXH@B0.;Y5N2#><Z]P?Z:N]W\(XSKV/,$>I]4C?
MN=;ZC;GP4QH/T9\_#P97,"_.4WWO2_2?\LJ^HX<A1+PIKFX(URBW-(7_9%YI
M@=)> B[&T(O@WAIZ]^!'89%Z:^A/(:GX=1B#DK+FV8:U?1EFMW-S%<&C"H3$
M\JL@CL%7R%.X]2 NAR&,Y=9^LI>7?5CFHH2U]8*<GADEP0B_FF#FQ%"&Q:SF
MO 6VMNAWZ0CF!/O?W%RE8T^M4GUU\/7M.4?1"0;4#02>F%DD,-<P:6OPM+R$
M-Q@$DV 0%>XKG[F_-FM#P@1?(2S=[<"TX451GI<A/3]'V-JMEZ3/\>^)@F+E
M>V=:U4CS\!H1AI@O2]+"^R.-8,/"\&15Y>$PK&YGDL%\1Y, )G^<EDA@DX<%
MSA4,$M\OB(9ZI7E.>W@;QSL(+F&G7,*F\ZIWJ\ ;TO<F=_V);L=U*)P=2E^I
MR=OP+N ;_G7 -&I]F;LA3DY>!O!,^!36-%)]$[QA("(#@_E'F<!#7J.9NKGE
M/.@#S"MJ$+E*JP1X$9A4ZR5XE34.>>M]*K'U,C$@3H*LH*7!_>#C,R_UESX7
MG<"U'X+D&W6)EY/6^P(R!YKI(@-]U^WHYQQO]#;H)B!E@S#/L8$3_B2D-V^\
MD_U&%_Q;(WET)]5: J8$I"CP0-^!&LVMEA/=CIX[OWWR_*:9@=_1:F0\24>8
MU ?",,=D:1F74</FA)N-RHPT4'W8>0BZ>NB,VVL9]G%ZS=[)]JLI0V]=5-@C
M4P?J31UG<15E\PVS!YLG]E[2$+?]I9ZLFRT'ZWP WNZJ;<3]XGM\E3<=YNME
M03\:U"&^K2D WU\#VEOB=IAM."_/JOWIO=9"ELY'S8(1!>E"<Q?-.5TAC5+\
MJDTC=3NV2OH2@+WA;1&JL[G3JC;O:;S=CAQ0H_;Q-FC0+=;R+^\Z7'>T< PM
M-+UY].><HST9%"F>2CM;--[=MO%V.\L7 K01DSG'J8[/;F?62)<OK8D7(L)X
M-:]] D:O#/+5#QFDB&@2S3N9Y^&D8&-D9W,YXP078GYC9.Y%9U-OFX;X>HXA
M=CM+6_!X =ETAPE[]8<J*)G4FS"N:J@9)O3NC'G]_O%V.]--4OC9HOO?VV++
M_^V/-)_IM)I_K'Q@;9,1O:7L?-XA/_"$A0.K/N16D=#SRQIAJ]T]^<Y1S_*H
MX.2:-M,-$\T2L073W0]A&X1)(VHQMT>'^W[1M=[B2=M=QA#DM%E@$FZ][1UZ
M_JNE3 &<(^'":[#-,3=Z5I +)M+R#'@^ZBOI,]GR#+X#/TE']MBJ0E-PCO=T
M88C&OI8-4,L>W0)Q&-/T$@9S&=*;$&R&("%!;F;HN8.Z56]J(T8W$5RM\:)N
M)TW 7(@2<$+3;R_@*MA+(\S;B?C=$.BD1A?A,#2X+>W])!W#2M&W>/N#<)+F
M48$ENS0!>EKL:9 ?P8Y5[PN:T8:LP+/$?K=XTZQ*-\V+H2Q&@6!VW?M?[!LR
M7H/Y3%FM;L>,:>,AD?P+,[9NYPIW2!3#Z]**T[EB@&H<^N&?@ZL@N:1KQK"8
M#:"^?&Q /)C2RR@O) 20P\32//F"-A/"BS"RZ@_=[= =<2!>4M(.@'5AP#K*
MP8/>>;&]L[VU\V;=@_M1NM?Y"U %61@'A,+"BN9FV/;PSJ_ 7K#>R:R5&0NM
M#DFM[X*<HRP=>P5F."-PC/_K0L4L[\TOBY(+,IT@4"ZP,\H58[3P4EIZK)'P
MV1DAW\)8PB?1"*'Y=6^(/Q[*\/#D,?!R\],+^K:0].R0R$HBT/EAGCO@[1D&
M%5[N;/8\Q(;57Q\X&% 5B!X3GFR]W=GQ[1>T9QR_Q!]:,^W&#[)P%&89OPRJ
M4!O%-^\"CIAZ&;F3KQ4?K3N"T%J$O $2#LEB>M5%EQU-YN#62]'@,T?5[1BP
M.AI8R>V.MJM^V0C\XJ"LP9JO/?R(6L9@",&69R.42D62NF0 N<QYH!)!HS"&
M[K?'%ZV!;UV_<!Q@K.<ZB.*@'X=*,.W(1D7$*68RQI;M&8)=.;?U4Z&1K$&6
MME[O6,*CI&%]?BFH3;1O8 $*7\GO0&O'$5)(PTDPJ5X#8PZP0T^"WYG?C215
M%.]EGK-<??Q]^.^K%<#[D #O]@K@?:H [T=$$\L,C"RE"YUC5JOS$7SBH;9#
M35M7'%>BC5"!<(37BM#R^0C&8%W#T>FDK/#FJB@=BV?EQ*="DQ+S(C39X%RH
M!/\_J."_:ZB3DF]^*YQ&MB%\SC4P=T8?N7[K#:^7\_G"VMK7>C=O.J:]^BD]
M_=3T&]0W!L;;?C9]*NU)KW_)>0XJQ8%,,-5GWLQ*9*6Q$,)()Q/M^H*G@ ]Z
M9PK,"5X=+YE$UA?V".D[_;DSS<V)"LTS[2O7K6)XD$_8/%U^[22TA WV38OT
M=#ON%.*_]112C@@IR )L%_8B*JD46CHMY\$V&"KFI?8UC)WYDKWX%D/SI6MH
M%E=@]F*J@F,MVPOL-:[O0[IC/9A2/:*<]J2KN/ M1K!F";'S: N?O;-<MB__
MQ0E$MO^@?2B9,S 8BP"\Z6%5;&6%A\;D4I*.#ZS]?!CF@RSJZR]0AM1743Z(
M00?KK\0*75B6NYWE"C.9Q#Q%9L+Q]G'T#:1D#"("9BH+?%_)D-B_04(3;.\#
M0D:^<V%05MO%DR<.G+('U@*\!?&^ X2+QL$MS,^#;AK-<;7Q]_]ZV] RC!T&
MTS8,\_*G#O@>Q]K(V=+VWW='LUZEQNY_])[/)Z5S-9S%HG?#5Q)420: Y>P)
MM*FQ"<[>4]@F?]/M[,-N1H$@H;+=-I/_YVVO#=;5Y6ME$B/*0$)_$X'$B),;
M#M?9AZ=<SYQ/A^J8&.X'3R.]R:=FO"ZZ9)Y0PLR]<.\^GAQ?V,]],0K&47S[
MB[>6X#Z.Z:IU/\?GP3I'BZSSSWASQ.+:MC?9H?UPD,*D:_3&]Y(4-$TZ\<@W
M QT$4YLH$*N"\LC*MMP^(ER!KV 9@UO#GA^$(9'94@8GZ3BQJ4E9J:>QSX(Z
MH[@")Z: )]J'OYSUKF#"$P/O)HSC%]^2]"8!PSK(4[R.D]BP[BH'K3N*$K9Z
MI]C:($>@PRXCP3# CIKVJF@_@/XNP7N"KP:@XA$>:@;.#-2@AGU%$#3B'X,0
MII:2/",R'@1CLVR;M/\'3&>N3!L<U_15:!Q:M],\MJ5JL/O?#G?8#VN]=3CU
MIQ@+-U=AXD4%;HS W1C#B--OQ<+QE193EF/JAF?8_H>_HP$B83['*^ &W8[<
M05*BBZP,+5P5U2/,)2@J//1' 1JJ8%6,([+3Z'>U'R!R%F7:'F6+2AF?>'D2
M8L(IGL>8 C,.OK$X6R:%^C&^(0A;S(S3OK?V87V&>#7H]V$:YO9<-;YIMW/O
MK^K->%.8"OM5]Z>_JFS;4QL3'D\P$?LNDL#7DCF.QIY^2_'0<N/:./X_!8[U
MO;Q,6X"PH\N83W0K35OI#7II4G/PG@?KVH:C1:@8<7KYY,4J0#\>IY35[J#!
M\!JPV(F<UGKL*>P?0LUI7U6F+\IY$6[#PH6,E66(75<M)-@:C6TRS+)(:<F3
MMM6A,*H3FV_9M_Y4:;[3OM6RRDY N[#ZRL>),:*M9GX09> IPZ_)S^!#3(HP
MKD+PC>%2PN/]ZJ[^?C4O#'/Z3Z%6V*QAB=^'5;]>8=4/B57O_.6QZA^V&Y9?
MXS?%_@+CZ7"=-7F(%5Y9FD0#, K38 @&8GJCXY]B9FHM;JM\ W"2;A\@FSEL
M$;JJBAVW*N>JI8#6\;*5ZPQ#P-6M="!^CW*E4VKMXWKUL&NPB8;^-*L!3(/F
M@^@>SR%[JKJ=^SZ'EH_PS.]SO-G=V"5Z.7S12H*.#6M$*CP>"1S-!@Z#>/@Z
MN$*W>FIYMM@23<7XRB7-H]WKD*3?YDW"/K#S"079X2&(L^&D>^4D5?@AA>S!
M78H*0<=M4'!49DD$+J#>V3H(CP$"P>4H=^[6@7' !T_+RRMY![=N,OP3_\YC
MBGTK3WDFZOT(O<D[N)/OOKX_<J([!RIV08 @H1,FG.$ L3!7<P819,O-+1Z(
MIEHVN]F#\$M<&4Z/0+"EDIAE_ 6?W1.,#M)>, Z+-]M?$1>-WEFK4Q5+,2DV
M"WLNC;$9W%+J:JLT$G4K'DNXMX.F$ZD.F"\ZS>B*8%TY.;YMKDFWHV #/8^N
M!O\!  "LP6)N\;PJ^O'MX>L[(J06@LAK9:)6&@9D$-&*.4WU=ZM92[FW]>JE
M3V@C2L++'2N'J=M1+OZ&UX-1M(67;$!0#==>>4IO;$B]VUD;KC?E$S  '&+E
M/!;3<SZMWZX5:.\/0$T-Z=!IW/">V>^+@19:4S3N_0WO$*W5N6=&IYWZN'D:
MYLFO352WTSY3M/GA$3=P6SCM)D'&2AH^[X=@"HSPM?GT(\UN!S$J$6M1K*10
M7+T*:GM^Q7KG>9ZJ8C>ZG<,_!^&$$E+FS?J8D4K"*)+Q,SSM9N3L@MA&2;=S
MFY8*_->IB'XC7JX6PF^:=M]1N$S3D):%![='@@GD/4./A3!?N1'=A[8"W4=N
MTKH=>:^R5F@5S*:  TC959.4^8RF@BU62-V]<[9P2%@E1-#9GCN&&0E2:+?=
MF91]D 562H:-PG7BY'PRKA@'*/119?-WV,<E[0>T->$)!'*J?]N2S9\8";9O
MH#,%FN+W5G+N5'BOP?JQ<\!AS,K\FIVEP1/MQJ])'-A6L%;5,=P"SI8N!/NF
M>5$BBMH5O;HP PEE&1VG0]HK&_/@7V]6^-=#XE\O5_C7,D&G1P$[_U"@;3EF
M[1VL6G),AR%&TRG4U@.S#3R-0'NFQ/Y^@[8&'(MYN)^FJ*20(MI7J4.@0\6+
M *V8E.AK-"4CS>6X-L:9ZA$U7Q*6],@EB$ZPHIQF@7D5)Z>Q FD05$4&5Y!+
MI9ZV <4D,P?O(@YIT\'=Z.$VN:A/RY^ZOALD\E&)B76*6X!(HQ2YS%+*ZJ 3
M\\[(B"ZG=[+7:E"  KM51ITBVL*9%Z@+O.PH R-]K<>XKGD%JKBS3"Z[*"]"
M_,-FN/?L!)1^&*<W5&\6D"F*IS*_8I!'N4(3\"/<8T,X. N!8U1,WIT^W,"J
MP# OTL&WJS0&2<V%I:O;0>DO>&2P)\#NQ@RHEG%[SK#;QJB<!'ARE YSDX:U
M =>W)"]B2>!UR):1=J4:8$O9YFQ/$PT9;L]+YEM'-K0!^BG&>OR:D+8B@<LU
MG=ZG7N_4E U."-+"4E%Y'U0ML+K\-F)+HY=@OU247*?Q-;X3"B]"]&G&S&PZ
M [-25N6&DB4%G,5995Q.$=DJS%01P08?'%^R9EY/A80V. DF+\=C*EK2ZV3?
MH6U+SMYU,UZ!9L!^$CJ#B6.&&QE!KX8 "5HT7BEKZ607!SH8H8XM],83]4>S
M(+HOR,$8*]YR]Q=F48G0 @TXBP%V34#I</\'1IT3GO2AS"-,H\/\/"52GX/D
MLD23;"']-RU]=_Y!=SNR/&JU:@X;[#N<2Z[[:\8JW+6S]W?S[QUI[G8:0"=-
M,FC.Y\LR&H*'EH3V>K'X8'G)!?Z##(DD]:Y@9M(,O0Z<2O#AJ$(OF$LB\ KZ
MGU&#2N2O@H'L,H1 *%AD\J[;S U5D:_2V)?K_UH#0 \T3Z<_J$5>X/FSI?R)
MV3)W,V:.TV[GBY+;WO :77EOGZM(8#[5+F;SYCP2/,$BY90CG#/EI%S"#CO
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M>XI(Z955IL1?#.(H(1:2(N1Z+ETF)*<Z,3F00&!O!GNMY ?LCH WZ6L6"3&
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MY5<N&$:C8XC/4N+7H.A&C!DE5F"HD1*Y\7XLK$14[=Q.MW36F6C6'<=5=='
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M8"W0EB [.BG%SP:Q"H91*CW4M?/E9H5JYH=?]1#4GC+L#ZD*!R,3;8D9C92
M1 !JGM/D#E&JHKXD.95H"1<X4RQ$V$6<V="B'$QNW$:4 82=VTDPKV )8J%B
M:!A)"UN8HV0\U#%6-H#5@'@&R*$[6]2S*JIY$.3FJC0*JZ!3(U62]>7&S96C
MZW@0AAR@VZF_B,;D"$AICD9%.KM.$CS6]IVFRY*<WX*+.ZH 2;E,R(D5 .N=
M*GZ.B<G)4/\#[!G2WPI8UR .^YHY<VLDUNA3B^_*=VN*F7ZC);: <U:;I\96
M!5.4.Z6#'#3-4GA-<]CMC%0=@YNO2[[QK ).*I$E)R3((PU'&6\"47V=U[A
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MG,.LQI3+# :7[^V^?>M]#O^$#PJ8]=YUF)1@2^.D_9YFW\R_T*[:WN:\)2%
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M#,1OX(92Z0 V_KSX%/H#PV;V<+7$XP4K12[VNYU][,:.$:$I;F^%!$H0T;D
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MJ'(6%#5F],\RJ5K!5-S+*T3"L704C E%<TW 9N,)R"C0'.<K*&^G+PW<ZTL
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MO1P<+<.4_G-U;F!E;T<<%F_0H#QLIWD9#[.I(T.%2ZTM)%+HY&?NX*BT4^"
M[]83ERL6WXG2[JQ0V@=%:=_^Y5':)4K\;*CV1VG=UTKKHE<P3G3IXU,J%J\,
MO>78J%(+D"V>,X\T7\^.UA61&@79F'IQ5SLSLF/&9%2I(*MV:EA#STDZ9P-N
M 9!3C:Q4W=U<,85HEL:Y5^O-:R+-XS!(Q*_6M3>[5:I#IZ9K>[,* 52RWJ3X
MD^XN9(!V,BLS6.4>E84Q@97F\S1M)N^C*RG+P +"\N[CR?&%_=P7HV <Q;>_
M>&L)XK0Q7;7NY_B\17W/G_'F[Z7A-A>^*]<$[$-X"VWQ^3AGT1AS6\:H1ZQZ
M5UCGH,A3-% X^RUAO K^R"(R,M%V%(NQGJ%&Q7/A)<8IYDE?F[<]36HU45%)
M S.9"EH9(OUY0MF!P:UT0SDPD:Z:DS+PAL;+JQ)GV88-8E-D\; KF]<,-7^1
M?EIU2AB!L-H;\*E,%<5AI6Q!LW;F,_HQ :X-BU<QXVBA32-5N)V5>SAWDZ4U
M4PI'P'Y3 *0M4#$U@9'&T)2^N%Y-7WQ:&N(QJ0A7;<LJ!)=P=EU2GB&1((-3
M&=&>,IPU= CB8.#)4OWHZXP3BDK(I^SYZF0@0:TY!5T 0PX$X _[Z1!?@VE*
MJRDH'"D07 #?M-LQK^7UJ0D]057:36U2=FJCZ-'2+]4VFG9%+4HFJF+-JH55
MY^=KG05-QYDF+E$4CX;[!]0).\EV1E@+@ZHH),*OGIC(+TOF9PBTC9$20#BS
ML'N 75>2%G@'K!.[;$@_A; .+>1$;T*NMN1GP2FD>'3Y'9:T4V J%M@J>I]X
MR]HF\/PY]DF] B*P>.O5 DKC0=(L?$JN6<0 1DD2L^D/<F5 L&<0^6OK(,J5
M65]8L'L3JRDM_71-311'/"T5,[IFP#49:5FC13#U=Y06'B54LT(XMDB$HFQ!
M<PC?C#22TD:.E63B&A7@4^3619:8WZP)0#6IZH@7"0,Y&A9/A7"CR3O4F>@'
MCB.G2EV$\[L=8YS/=[1FW:?XJ'8;.=ZM_,9Y741[%;_#/?2V-[6+;,@$+45X
M!_O%X3^F (S>?(Y#@O$3NWZ"RB=4H%_&5[& $*HD]MRJW5K=0+F]@S@&U;;7
M*C_%TCO>;]-LX3NSN,UVC1IZBM>\CG8"M3MK"1/\K'8L0RU!Q\'C41/?B1^_
M7.''#XD?;V_^Y?'CYY#ENV!Q>4]%+=7Q<AIDF""PAW%X"VO6QZTZ3C&.S)%2
MMMBP1%$%<CEH.IY@;X @MQ,Q[#8TF,A@W_&6\B;XGN*D2N#+V.AJE%'!6I6/
M&JML4IUI$G[.41T67C6N%D0Q<LY1\V\:-%D'C2,Q]BA5)ZN\./NG,@\$&;&;
MHH+,AO')M4JE"2=",((NT=R$?X#?->#"NP S."C465C-1:25DMUCU1X:W+=A
M%+JYJFYJ:77<0+PIU4F[.J5/SR1*AMCF5#BO\Z*Q8)IEQ94)"\<SOGP@#19,
MZH^J(:S*4V0G<L(/R:_']D+-.8PP*;H]ZN+#ZB\R+*N*5(VK$L#=\'I)DV3@
MO---!M&$,*%:CU/U"N3WFJ8GC*S0:&O8B4]-T^H]TBJ=7QN&8^1F33(8-&Q2
M@4MJFUVYE%CUWP\-%4#E8?KW)#*Z.1L_N'%4N%[]D(16.JTTDE*:IFQI$AHN
MJ37<%Y*#9CS& ;5.HY_(N'/F/ QU!R;DNKM)G'0@[BA7%\J&/";*&4F0YW6@
MX ?]!-0S.1BB<9!Q#B8G, 4#W2F/T& XA-W&:!6'5?](]8(C@]FD=#EP[P8V
M_VA=\04:#36\OR^0&[<(&J-^CW+Y2W>GHP $_-LT2P&-=DG6<%/WFOM$/L5@
MGXWG3#E'#,NL-#J*^J4<2)C98<X7BZQ:*Q=N/RY_O5'E)FO2K89"!6G1-MO$
M$"A$&3@)*1X;&(10WXMSL>[#L\F5K:"BOK5(JE$3K9+&B*1D(V?6!9TF1M6[
M<2BJ-&P^\OF000=4'S(5N>7R$[.^"/U9*^O;ZTK$[K@J$L*4 0[3D,](&:D7
M6% ,D[+0FL+.U^#-",YV.#/A[<MXHE.],CQ-K4,? SD-"3TL?U4-]D1(0,ZM
MP(+:Y_NRYM'(^VC>_DP1@9H\03O3+FDU\:0FBTI5*9^Y2=5@JKY+-=H@/FWJ
M73-"M]E8"M:1G'=](%OG!D%\5GA 5%H2$,VPDTT*,F";*$;TG'@"SB0>UU5=
M";.J-U-E]U%7:W+*"%0I4NO@>N4T$Z42MTFAO?F&=U8A)725<@1[=1=Q,^#:
MM:[YZK(\F<)NO*]F(*[&50(LU,)NCB]W*[5%U5]R\IWSOI2/:44MVEZNDGJJ
M)6?8;(;=ZIRXVC>Z8L&N9IXF94V4O-*GD^;733=5!2^5=]] /PDOQ2-8!TTB
M.(2&6 ..,8\)3OS0;MW%Z.%2-YW7NN>4),S>=,WW-BM4VV>V##1N&=DJL!U&
MK>*]UELW@\_;EGW66M7\*WQT1%U0.>YB_;#O,!?3H?-A7:7YFGWN9B77AX0-
M"DM#(9!0(*8?<-D-C/<R38?H:C*3.V8G*UZ-MHNH@L<,C1P;.H')LYE'''V;
M5EC3].(/^6VT(S77#*^9M")QE!X+5KB[P@H?%"O<6F&%SRS-](W%@JX='<HQ
M[7:.*EZA>$6Z,&+$]4D.[]9KY?%$N3XN6+6!CM/-J\6(CY*\)-8]\2.=*!V&
MXIKUE>6WJ1AQ:,7#R&LESR)7(;'<BA3G3IL=G8Q58+E+*S#)IZ%V!O7Q4$OX
MT3[0/(-RCF2=(U&U"<UA7@G 63X=7X%$B=B2C7M_8\W:!#_*HH!'#"\>TR%Q
M%4JGS&NKL7>E7[5A<)>:"X1>KICS:5A+XU4T-9S.1C_3[:X;6T=6V.6=(B(G
MCR$2.SA&9(<#Q5H"^[>2$2M!2WV-Y$A0<S$Q^2U:J#BX\;U%)XWZUB>QE+DU
M39^1*IVI6QD7=YM%C(B@-&<=R(.M$A>H6;6G7E7ZS9C^E@*\EE"K("",/:N0
M\ PY1F+BVNXB&;VA_M*Y55V%X,(UKC8F4A:T"LI4"V8WQKMO;7AA+02R?LRU
M([Q%-\2,5D]Z86?N#^W_(CVJ3DJUL46+9=+(=ZX(3HH4,32G67UML^I,A)FC
M6>,C&@8S+ =DXRI9$*EOFT8U;3P<L*LY%F'H7^3W+F.)8QPCW:S.CY<9QSHS
M36UHQ>W[89#5]3;3=L5F%2;(Q6(:)NBZ5.<YPAG<^*!'),ESZY0YI-<2.JYB
MK#&\(B7@.$5!EIQFXLG 9%/&/JMY<U-SKMKX7Z<D<+?PPHJR5FE!)LF"DC:B
MANV=>8V2IR9*P%A#HR8:G!A,P!>S&/? M2)3IO)DKE[';5E2V))H@IB+U+#4
MB9/7E(;VX"*FN\4T"@_!=1JM<^HA\<YL]^AS(!JY*'M-U3@&YAO.9C="2&H"
M]!B27 26F>"MA<2>6R\YXCL4%"-@ME/8"@BT"US"9@%7]YO,2@E#L&R/0:)3
M.HIMNX3/4 U@<SFK'6$-6X\_QWR0IO25<NTW7";59'+**=WMW,W<;#2TN3QY
MYJ"JAY'(ND#W:)[#8&.+J\98X3H]8)KI:\S^A1*'.?GY!^?8-P6:0#S;,X?G
MS3IM4'</J@(JX">?E&Y/LX:=B^39;MZF9FZRRFLL)XO3[$C(\=3_<V QKLKG
M?<ESX"&P)4$G. *MAL=#F*+0OX0K0"GAS=#NL6XE[J3:+7QQ+=<.:YI,'H5P
MC_+H2?2Q 6Y?^[S*'7SRZRT)L-YE&<68'8(AMRPHD1,XH8HBEW?$:?E:SX-E
M@=C:TN2$E:18%3U0\D'*.:[(!V=3J[P7&1_FY=X$K']YK'H-IHWW4574OUJA
MG ^*<F[_Y5'.9U51_Q$/>;;F\EI.NSZ:,%=MGF+P[ZT%[W9,MG^M%MR*_1E7
M'LL\\ZKFTXU6[.%0T*8O[Z%J&BKN'YOL"]4TU(A1/>1%778=_&+O[J3?750,
M?..9:13$[C6)N0J6E='F;R"73V9Z>D:)#17JEIC8EGB"=J(V(L36,' !.'IY
M1)UR,/',#*K;28(QIY@I?GT61]6 T&-RP,+[(P7?\E&0 ;U5\8(SEV<,?(_?
M3',.''?/H50[%R:D ^DRS&Q!/2)!=V]D-_D@>,+<IU)"7\&,J>IYWNY +ONA
MTR,H+_N"&FO)D.50'76)LPDI>MGO%VP/&9R(R=VA<,)"R,L@&\9BN]9]D+$P
ME#;E)=F[6V6CP1%,.)7L7G9-[8NKG=<9N7 9J1I;R#>U?GX44K>UJ<1N"OO9
MT^%%L5YBK]N1CEZ&"*5:PD,MF12AFE>E7FTC4O/G9%(3ZH@U-]Z2A>3I5+L7
M%5)*-8WS&Q&4A=L=4>K4_/V.-, 7<+\C;W 5))<: S?L=VN&'UI!$.BXK?MP
M!&8)$_DJ*F4X&D>C(,HHGJ'YE54QV'P-QA2JXP!+8083G^.9Z6:!JN1)&;40
M:]]2?G7&F9AJ&'XM(I8Y=*.M7+N\"H'-_UKE>JV2YO9O&3V928WK-3#C,M7'
MR"$L;N&U]=II;;N=6;RV;(!@7Y$\0C@MH?1H1*C&%.>3PZ3.?COC[7UFTZ'<
M);,/S/3.%CXC<:!2OH6%SOIV.OHI3A($C3,UTS;?N5S,\IZ6!3D*^!)7*<Q^
MK/F-PQQ6(B@TA0F3VS/8AM^,)1=V@,*FJQ=ER 2=78=Q.F%.!>K61S :15GU
MWC5OJ(=*\7M[[),4!P6/]#UGTX'H).DX&CC4HDX4AX!1.BTMW9 +L2.G_!*1
M2E3HH@^=8)ZJ[C.5"A$0 [?HB.?3.NQ8$X8)G]ATM :XS56J(;*3NE$PWVI1
MAN)A-AEGQ1G::5=3*$VJNM$P>(CUJFXQB07_T#/#FVZ'VD2>%RFX\8=_\C*H
M+::>+S4"L0[MZ/:2[G5B)- O>N<'O7]Z0G)^3G4MU)0L+!I&2YGD,EQZ.!Q%
MT;@<TS^#/^F?$C:CR9-QV7V;_E17RL\S'!#_7*ZT>_DPGN9KS'V$#6HB8MZ\
MX@O9ZN$(R6U>A&-M!PV=OF::6N'CT?%93YM]M#M<G+<LKM*,JJDQ_<!:YL#K
M!\DW.BG'V-D0?@4OH&=I& YBQ1491G1CU<T3;F0Z?<K]03R>2H'^9Q-,(.-$
M,H*<PQ[^L+A>VUPIO\Y^>A>.5I6-,XNDU9!F#:ULI3*3L*1%V^I-8VUM8FS%
M8.+=*5M_((CX>@4B/BB(N/.7!Q&?"WZHG= MY80>A)1809'GDX3.U2^8 =/*
MB@QZ,^7?C5M^)ZH'JY4:.\5P@SPX_<1<(GM$19PC18YW2XB58%T<+M%76<5J
M5NX.WDLZ8<A;P65T<VEQL3ZE71-:Z0+7$5+'9=:JOLU ;AHLW ;=C*X-6ZI4
M"N-KZXY@GTN!>D9DJ]2F+$F3%T,>)QW(;H*&<[J7SE?V3%!1I!JI$,)@/1E^
M+,^IS(5.AV.4C[Q8:1#%^-30,'QHTG^NL!&*0 T'[H'EYGM2OSNM%98NCJ&6
M?F&A:F/L:>*:+S6X[9<O<':EX26GM"Z7 W3K7LG.>HM3G462I964XS[;?=65
MT]D8'/&%]_Y;G:VO"<9U4+%^J,5G:-,*,*MLHW V;>^^M3E]F[;(QGFQ^7QU
MNY.I(6-37IYX0E9^GZ'@='!F!_PVW 1V/IS]"TYJF?8VN-.>D%Q]N ^Y4@D$
MRY4G5STKZ@$#_C48RVY[4&;3;UVYA\XB4,3^V#($VQJU1%X4T,[T%I25T;*O
M*/YO9L.M#B!J+[[P05]<^#,HJT_S?W)#&QZ=5\D<,]T. L<!J8&MOG(YL6:K
MZ2R15'HW E@)M='932HGS8L)GKHU\X-*.50O:J--N;H105NJ%'6:U3">P_4?
MDMTCSCL%:GBPK>2V4Q%@^=[EY!(41AI7Z49!.'#KQ-SP>O#\4FT[J?S@]EUB
M!U4CB=CGRZJ:UZDF5-@7%=3DB4M=G'!- SD 6)"/PI#=;C)D+0G11JL-8LTV
M4/-0:#Z,UA2%)Z=2@WE*UQ@%2%JW%MMKTX(NW\UL34CH09U1I96KLIK39J,&
M+QN @UG0@%?1@*UXB=JB2@/:Z^!J/!.]=U6?K5T>A]#M**$[IFA5+D5F/39U
M"0(T?-B895DF"L:WC!9M1R'#M=#U5;+354F$ 12')=A8$EP:P<M0$Q8&*I.<
M8[VT!4C,,:<QR(;<6@H5+H*C]G"H]IO&VQ NM09"^1<\E']LG&Z@BW@9$$RE
M8.+/G_=];^?-CO<E&$8Y+GOO.MSPO5?%E?<Q3K&IN\(/X5^_PWIMO7Z+<3VB
M!>'SX,CTNOQ$O2[/;Y,AQ;_!9,F_29@DP!:Q!*9]S"*T/3_"J\.7OX)NC'"=
MK[*(DE6I_:7WCV"0]E''40-:='$UCGD:!_\)G'&I;[8V-S=?5D:'D+)WO@'/
MN0WAMX?YOS?V]$3 3,>@$_B1^^D&S4>WL[7[9M?[D*7!\"8 N=Y^^^[\Z^G[
MXNK=S_B_+1.SN?.J?6(^,'[K'42\F:=/2K=3F17O1TS*;Z (<^\C;+244H1T
M.(J$9'=WTSL'E7?E762W=%B";H23<O\JR.(4;@Z/W/>VWVQO;E<>=H$R+DKG
M2Y $EW+&/KX9$"<H(@+["NMEXZZ*B*QB=W.3G^X=X%A19PV"<H!VPO$_O,W7
MFV]?N@\_""<E'!<2=H=',"T$/GX_S28(\8>T!%E8!-EM;:K.K\!Q B4IDW(.
MVYX2,FA2=M^^]3Z'?\+?!3P-MG-2AFW3LEU=J\]I$GC'F/F;7 99 .N ,_.8
M4E/?K%#E!T657_[E4>5GE9JJC:.7RC@2'DXQCBZ:[. H$48G5)!2J^H)421H
MR'[$A3 :AZPWG*\GL;AX$1B/6&J19DPM1X5\BDB8+:<Q*ZW&3#RBD2QTF%NK
M;DR-P9H'TMV7JBVB2F/#EM2<XL8JF%-)..HG;<^_[U7T[^M)=)5N4=SV0/&/
MJQHH*6S23H#B.\!?O[$>CO_A>W#E4U;GKK2*HDP]F"#H&9JOMX8<C<U>\F^)
M&E09^/6D*Z;!5MPOU=ZMF%KF7*'(Q$U6AHF7YMKJ1KG*0KV@- G]T.1(I+'B
M&P<'.;<*XAN#' LNF20N8N3?6K1N9XY56V@]AOI]K,$GJ6H,VBZAS+RHD+S,
MA?ET:4I[N*=:PAV8E[>*B,:P#K&I8U&/>QQNW:[27)\HFX+6YW-P0[.*3V,L
MX>+7HW.O]^GL\/#+(6*WO_8^?_8^''J?3OYU>'9\>.!]^-WK'1]X^R?'YQ=G
M7^&#HV.OM[]_<G;0.]X_]'X[NO@5;G+H?>[]=NZ=?*1_GU_T+@[QC^/#W[S?
M3\[^EWYV\O6BVSD[_-0[._ N3O".'S\?[5_057"U=WIV=+Q_=/KY\!QO<G9X
M\G'#.S\]W#_Z> 2/O3CZ<D@_/>C][N'7,(ZSPX^'9W@O_9S]HXO?Z:>/8PUT
MA]9#PAD(8OR5.SQ) !+32GMH[,1L(.LJ9,/[#QN%KU"J0S<W)_648G,&*G!F
MELH1IR.#@1N1"4+4&-H3[W8HOY$Q0%&ZJ/S5DU"Q/(ZY>^V<O)AX]S61G#"!
M6,P,1LDUW'LH"75EY7>:O5?EO" E[&463*ZDS-2P<C7B6V;&./9@/ZOY2:R?
M9CU/9EMUAIYS>-V.<Z)7N'PL#@!%/D'#K<P+2IN=JEK5=Y3Z3DH-[H4")=E=
M:Y1I0R)5_W:=F$6RT/1<LQ($>=;X2#*C>!RB]L8@8#"[0YAO[&(.+_8Q&I:#
M"%_D#(Y!S" VDO?N"-/:C]Z[+3('FF/ *I)@H/47'0LP >^F7NL-X1<KK.!V
M@U++;44A+-X2KK=USC[FE;C5_,>*W$.U81];+3XB*JL"EUJEY+Y _[>XXE+K
MC-)("PO%Z(?%31@F;JY[A=3"D#6H\IU*_-*BM\ L!OL*W=LP]P;!1"F_$ 2K
M##3>2&:9)G]T/Y'7'V"26FY2 <"VB_)O:@:TT:6(1JQ7S&M\I>[R['%,IX%/
MAG)J[<ER;H0[L6\2UZGR/<\]:09(MAWGO%DWJ/99)88D[*BC\A\#YGQ!2Y!Y
M_P,[_(FE,;E."<%B>K)51UKBJ]5I:.FBF(!9%R,%$S)08Q8K<H/1T@W %H_(
MQD.]"*^6WH9A[N9^"-#/?5$K1><X\"#/RS&[)S<1417AWW"#;B>P]J499>;L
M2T+X@^M:;5TCV[7B6VU=7ED5MD I[=I>%=:?<*^U*+-#^B-=3-!8HDZOP6^(
M<HS)ZPGU9<#/U;:V&&&$U@+AJ"Q?IV4PTVFR ZH]JR03LYI"8)K..-UKZU)\
MO=ZZ236WB.L=&,%0S1X0++MD3S3P^H@;<W8QS;P]ZUQ;0"GNDG<?YH5\/(Q0
MFRD:I)2*+WA?NKZ*Q(6:!LP!!W0;G.E"U1>G>:B$00@NU--AY:^CK"@U^;^U
M-3)+')EE!E[C*OI1F,6<F.#;%2;XH)C@[@H37*+(_TA0\*?W5+$M2K!)EQ0F
M?UW#1K[B%"(:G"R\+&,L2N 3)/B35+RB\A7%J>,IVF:;9A?892OHMPDCH+0N
MF3X&NH<,@E WW1Y"4S2+!V#1++K]WV4T-P$EL# -$74FR'6#3 RO(ZNSW-3A
M>21R1\W$8Y(/NAWU -T/1[45:M7H3><Y[H#!E4W1HCX96;I[6,[H(?##O ZK
M8IMJ^'3I+,G<QOF&=PZOAT8V.!]IS%6=F)DS%ACZ*135'B5\6#-QFFZ<ZC;)
M"\B3#4#0KJE \Y IO_H8WN>Z;T6A'=BL4(S !C/FRK>L>&U)U$RSA@0NY2HI
MDX!136-"<'_QINQMGXW7OBJ>(TH!V2%$GZ":H>:>,[0;U<9$7V:U6Y_^EDRG
MUOP"3+C>\AH^DZYQR94I>H/-FAM\M%(>*8T_&K]_$C54WR.5]/X??MTG;HR>
M,GJU 6G?8X8 8^?;N218Y;AZ9TR[T5@Q0 -6EO>?Z)[G5H.V.B5)%A)>+_J9
M81]S78%]V+Q+8E'+K+['DM%>&9#NOV-N,*_@2CVO\RH_4"+O6]OW<H]R&B.2
M.#OE\.W4"H#['I>D5((<=SN.(*O$RBM13HI"!CQQN*OFYG82,X/JQ9B]Z21_
M15QK'PJ#<:6Q >86;9.<[&]X?T<<=,_;>O-R:^W;^H,NGKR>*(!NAS6 >DF<
MF=Q&$D;@U*0W,%G+K>VX]U;VBV?A"VEVMR,S-! 5&3H3%"@;#T4EHHQOX8CQ
MA9IEJE# VWO[&Q\WSK1,;.]N;[S9!DV_U&Z>]S_!=YCA^MQBK?.]S>S+UQL[
M.*_+KA^Y_ZF=-;<S)/;C^=&]3>K.F^T-E-;'H,-T0CF=V/,I>3T7"VKSVDS8
MVW<+E#U(VS:>VCA!6T1B9GH /(;)PI.HVVDU6=P#0+F8*KCS43@&#D)B%_..
MP$_/:'*H:[RX\N*9$_R);0'+6#+O=48UPZP43[A CDWOZ$@70:;#X0O*"/5^
MPR7AI%,8':5&<[YD@L!YAJ48A5@<BSW^,64W[FRND,P'13)?K9#,YYC=N*W9
MVR3GNMLYU5EF3P9B>G?TWF9JJR5G4H8+E8/Q88=&:A8:^D*E574KUUHC#<['
MP72SD$K-XKC2KA<#CIE$52G)1E!<^# )4RJ#(\9R19CHNV%J!E.3\#*E9G34
M]:4"<!)T)# "!P-U^DCE=57Y.S/!22+H3:H+]@D=AN,;WC;WY?1*0L/OI$]Y
M;.J<1;"$@;0JMO KJ2',%8L_F@W4T%-WPN7C2T*DY-#KO%>Z141I1]RRT;'Z
M^J"?+S,8Y!"U;)K]@N,J0G"E$<I2SU$\B<*3+YPT\KCK*, &$]3N&?$_8E'*
MTB0:L,1@H1%.BQSW6*5-V02J.-%C]CMUSJ]M3(:C=:D[LL.OU?M*V1)S1371
M[[NS:KT-#QQF@JW5^I*J-@TP=2I_=YP.F8A?.@Y;A5<X)7%<$>QNAY_B2T&'
M1<8GB65K$AZFX/286G"L*TB)4'_]+/G+?21SU])"W%Q)UQKS#,Q<0HM)6CY2
M.B?'%UKSW#*3S^IDM+G[U4UP\Z;DMW$2@S)>6RIWGP2 "3KOZWD/U'50@"(J
MT+;C9*2C>M=(MO>HTE<J;P4D.^]YUO7>FC(SR<X\+?L;WN<->.O7+W9?>6OB
M&% SV3BX\4X&1=I'*W7[E0\'R>;6NA"2N'G%F=M#(.UCTK/O7>-TJ586.%RG
M"PMCKS@[*.!Y/==@$$>L1G4VE),2X-=I+$F,5?<+*H4-QIQ_%0R'F6E?T/(<
MJW46;_WJ<)'P(Z9N\.E-?1JX^2<<(-A3@]_KMO5I/\KRO@<[Y#O-_*V5F?^@
M9O[KE9G_J+?7HNP6"I8&;S\E'4D50+4#XA:YB=R\2>0JA0\#$TR<4*2?3!91
MVV"XU-+. MN\U'1_-X0J3%(5 S&V'VC6&!N3<24G%;W8UJF$43&*ABEDD>HD
MI USZFHVLYK%>6>F9J*L"<K^7,YY;VDXHVALQ5)5/.XV,MIDON>VZJ>?WN,(
MINF@G]2^,'MY F<@3.P+JG3ZQ=O=>(ERICY%-24?.EO=W&;_!%_U^']^>OG3
M'6[Y+V0[O\B0"N!WY"#SC2*YP[O(A+[<_IMYW%W?JZ+JGL =7RW]CB_O?LN[
M+N'#BN,_OQZ>7W@'1[U/QR?G%T?[Y][1\?[)V>G)6>_B\.!!7VQUF\<B8JO;
M/-V5^'#[2YO"V*DZ *X[L:7<B84TXL_YS]XYVE43=+?#^(E-U^.Z#?DLWWV7
MU7(LZ38$&7W_>OP+\Z)/LS G<$3X6RZPI+',D/O+6B%Q+;_;7)_MGJUNMKK9
M]]ZL&:7YO^^.WI]K[)\P"?"C_UEB=NY!%%PFV$ADD'M'B:(TP/B!=G'1![;:
M*QV]_W^/[\49&ID3]]O>\TXF%/?Z!6^M4B178* "V.X( _XU,+N%97*Y8HZ@
MW$_OD<WBZ.S+X0&Q9?3V]P]/P5OTO7<?\-2:/[ 3Z/ ,=N5":A/,V*<.WQ)L
M7DYRZ9)5)O,HGIQ]ZAU[YX?[7\^.+HX.SY$B;TD/4/>^Z!U_/OQ=41.>;"SQ
M$;_A[O<^]LX^G5COX"_Q"4N=<G!CO"G3;H?4245PE4F:P88L)Y,PPP9/L"U)
M/IW_<@CZ"<.95;6ZYU6O8\V$<]CF"6[?ER=XAE'3POL MP-79A@]!A]<5FUW
MZ>#AV\7N.,6YLT^\!>XXWVRK][\[9OQT_,<E>6R'W&<2&\<*M==]"/)S=_:T
M^;#TDV'J>7GWL^&)GQ /H?"/_O_VKK0Y<:1)?W>$_T/%Q'H#QX"&T\?V;$=P
MV&UW^R ,;D_OMT(JC,)"Q4C(;MY?OYE5N@ )! B,#='1W3:'*C.K*O/)K*Q,
M:I*&Q=[87M.O4]//$?->Q>]5_"=3\;/\E;V&WZ"&KU.+&R.37#F6P2:'WZOY
M5-5\$EGO=?W"C]DQ#;\.I>P_\U*FK/=M9GAU<OR2AN,M*(6NQ41DV297[3'-
M,1BI>M<!MI_7])^YTHG)X4'XR(2L^\0D*O_3C>,G.?8H[4\X$J8[[_2!1904
M4SZIF[ZE[VV\OQ^_MNI7%XU'6$Q5<6&J4/A"DN++\8:[+J9\7!)7)N=M;,TN
MBRN]&'%LJF5^+KP8V[$1YC)&Y#6!F_ <*"2_O_^J?9V=J+E&>II^W=BJ:)LI
M+9??1J[-20VTLM<WTR?UH\"H68>HR1F!I39U==%Z[F2*^7*V6#K+%BN5X]68
MC>]6EJH Q,?_^/I?A=.3;#Z?Q[^K2>%)7N!<A?59K<FVF_ETET"H&QF9:$:V
MW6)(80U\XX:&[;U:5.W9&U@"I\5M7 &W^G^<7GCRQ47.;9=!"M-?%_7%$<?K
M*G:W"4D@ R(XQG0I92U"*&WG0GB\_!860K4/Z =PU_KD4#S;FL5PJ7>QYV)/
MM[0Q/;@VW@LI\9[N&FC>U4F=#O0A0#/LW<B&:X0#VS/[-=ZM;FC:MQ(%_&"C
M&C75J:G?>C$L-_<)_1;O^FNQJ%1$;)2#;&)BHZY7*$( 4_'_Z/,!?"C1N-,Q
MV)2CE<LKY[$41PGT3$H3_X;3_\@:(J>D>*Z<(>VR(E^ZP8--/CM14*T<F4O\
MA?RDAH-AJWW,+942 ]7<,A4&"K$%!O:1OXWMJ_F!OIH?Z,-6>MATKU6%EYL/
M]]B/K_W8&@OBK5S98)$"C>-B2+;AGJX;[:O__0.W4T0P<0%:Y;K)3ZT:>18R
M/\PUO;[S2E'6/8U>_B[7!<5[_VO3XJ)>C&.+!'&-?'=,1@IEK,%3.'>;T6!-
M!%F7H=5C1C>$E)3I7;1+@BR&!<D,'3NG6:(YJR=4VQD,#%E<0LJWP536[S"+
MG,>(6(1 =URN)67R_<B2*)>BZED;:\K"PI0-J.;+\,.5:=F2P1+!I<H>+FT"
M+M7V<&G;JS&EB)_JN8*/H)J/#_6K:@O1TW7](EW@M#T-LZ+16CO4ZQ3[)^(M
M;T_E%Y7S2OX(!C&QD*H\1]0<>#U?RF/U]?-S)7]V=I1:#LQF#M+?<9!$ZOYD
MK^XWH>[K*:O[7&$W%/[6[;7XC+1Q?5_T]?WE]5WUAK0O'FY)Z^KBHCU/XZ=&
MS3L-?/VU$>DG899=[/!GJYO;VE@,5::<K'.TV=499HZ?GK#'F8ZSH8<':$3'
M2/HX"?P^$7A2D+,'%.V6R=\L.O##ZP@P\H P2$4Y%9%^$,RU;3O,^I_X-*FX
M[\Z;V%72\!?DH6U1C1'<3TOP,;T!-TCYO5?27$R#8(%D6FPXE+&4XU7X*9RX
MD9=,^\_*\4;9NO9Z)E95U7*PJ<N*<^/QLE$N)K/WEF!@7-=ND/9;S/C&MHM+
M2EZ$1TOY+)$J<9-K1^R$IG!Z,O*_(<>RZH:N+K,?P"$Z+9T=C56!WR0_OP2&
M6YQN,%*GYT?OLVT?EELTKET=8)M,TW3Z[T-\DXY$'+H)YI4O(_D6Z^LY9("N
M5N1N90YP[]I+,'"!#27<'2SNT?AZ%'>TROOP=!5#\?@9N27@#?E#,5_<['YW
MR]6-2 V(Z@&@>UF"XP+\#RL/ R%W_-6U&1747L7-VHS6 -@1+1M68:?]9Z%0
M(9V!O5':?8K)LCJKH)P5-ZRS9%A&M)O36%_\L@3A\H/BPZM=MFN*_D8P_;?4
M@DWH65"2&?8LQD@?GMFSW2Y(\B!,M[ QD336>'1V'-"2P8"?UVR'6D3%2N]:
MT"_6[1PB'1BO=;;%L'$.]N61'0*QIXS!1&L:DV!]>'A9MGCA@Z"3"Y,(U,H2
M> 7>QZKUPX 26(T:'0'''6<H.L6(EDBBK_%)WGU+,@5OHLG&5D%!TUN+/>OV
M4'0=HD';$-'W!HC3O#[B+BN"0"H8D1,:T"%CH>Q?Q)3NL[U>R[SK5OA*92;A
MSPFF$90P>VDB2IL[%VLOMN5F:]3O<",BQO;??5W3^/ +-@_S6A:AMQC0#&(8
M^*B3"M0Y)AJWW[2<8Z:)ED1KX?HDBFVE5$F1<V J(-MV^GY_(E@?:/U>,;;J
MEW6S8$WKHMFF[=[WU& UCV1G'MA<W'GN>>V-@HU"--V6K1$TN;*)#<9=VG;2
MH;9N9P,:*.R /H[@OT!*)_D<K&XR8OA4;L(7Q!DV$O6&]U1AAXL/R(WM;ZV@
M+R<9>O8-_6(R,!P;-((<FPRXCFUR4IQ!&<^.SH8+AU@2W ^.ZM$P*T9^NH^1
MKS=&7L\54XZ/?_[;HXNM\]@TJ4\9_4MP!W :<36_"A5&,;##W.;.Z+-@?SP$
M!^RWVUDL&U3C!&T9&'.WQQBV4):]^1C"$ET+G5A^O1>M(6D7[?J43E\ ]"".
M,$=DJ/?# (AT+>RRAR\BAH#_46_+3FC1F&@"CTS"$)SSP'K-,M\=AM;#,]\D
M+,K#@W7(<I-0O/[8NFXN ;Y/RV>E\@VIU2J;=;=;UW=+4/O8DO0"N:6-TOL=
MP0*I<?Z2>W!, 85NJ0E:SUHF1C#C3JRXI#SSXJCXQ*PKE>(#L^X=RC%F7LG;
MV++EN17DF!IN2WA-+T6D..<B7(HCS;YUEN) L?>Z4APCYA)5BB/,OJ8T >_7
MOSW,+O@RLO^I%Z)<)J;EVU,!&DQ-.+..[;8594-,)U89TWR7CW>[(!J9,6PQ
M</;0#ONQ$FZY=E2TI"O#*)%94449 2TJ,5E3\/[ L6S';; [X;P-_+;>'E'2
M&\9J.L\<!"[4,+P.;)@B&9?481; 4_4^[X0;[&5D$I>.V*:K&SK&=V6G8 R#
M"$+?N&.(YJX,*PA2@DV60XC$EY'$,-@5T!>3W@4W&N" *:$1]HX>#Q<HY+HK
MVS";8X0!O.#/3-19\GO\!01F_4=Y5(&DO:[8+EG3TQ<FK /.+SC! 1<!@LE*
MDL>D)$7@=X#&D7M4",.-A:GNDL3'>:#):SJ-#.BR7S9V37:=]0>L#U4I% L>
M!9A2#3@-3UY-S;&'X)\_L&?'H$,./U:=88_C*I.;FV3<@?W'> $X!4\X <'#
M,,8H.\&V!TZQE[.CNBW%)YM(^H]48%F&Y>#V=DS"L_A6B$<Q,'Y!M_K$IH:,
M&XD^DZHJ0>DK#B";_2+.9):JV[@G=%NUF(26,#QW9#@#L_SUKJ[ZC=MAB\#.
MH'ZK;.^Y,IJGI!U_2"M$<;:/0;Q3#**XCT'L7H !T,,W@W= 300I+4LA!QG=
M10318 -NZT))MRW0VT'K\@L'[(^!<5JP377\P<;0:Q\<$N<WZW>X8SW'**8M
M++#X][4 3+H$3.PW7K.R98-WC1E@A$$ GNT-1T(.#_J8"\5E *7C*?!Y>49^
MYW< %FCA.XZMFWA,@T<[L-BP/;N+=$3PPXN!^\-GA.FS_2<>'J@CF T_X $F
MT6UE#_Z%:]+:?U8"._H8V+!"13W)^9;ZXK?:HR;LJZHZ! N+J5ZB&[.P2PQM
M*UY%ZPN(3)Z9R2QJ&*/# VHASOC7T=UQ)6WBFV]\G,$L6% #?W%C3<(;<BVF
M@"=B5)P%/+HR1K*3LJQ,^09V<P(%>*G[EGUX\ ;^+7RD)["E>(J4%S?'0CJ>
M3(-XEB0\B]CI5;>&C@^UNE0=RH4P,?D!@R#8K&!9F&V4!5AL _2W245=ZF":
MB)PE]V$R3M:=Y!N>!(R_BL;1,+PXV L>\45^-&":V#T!X*AA<W%FXA@RN :P
ME[\!)1I :FZYDPBKQF+/U,*8U8S,UU4VD>MU8)2L*XBG[H&D1072L8<P"T(:
M&=UT(VX@L_#U1D3F-/J^X[$$:N+6:.!+XQ?\E0LZJ@\[&<<*'^FV+NK>^O>O
M=WC@$03&W3TI9(1)&XX)^EE0+.Y2HK-1$_8-.Y&#-%\!$F;%S^X,R%0$Z36$
M.9EX*71W4TP)K(:P? X/ @'AMV5!5HVKCG?X%B'B0"87=<&<\!: "QAIB(L4
M:QY*9@(MY6H[26((22N'![^ *_23P$UQW:V  'Q\%S>DV"NV+%MZT?A6??"V
M&1+QQ#H$WA.+_>WM30'=H8 +!WLWV!D2PX?BOK 10I#\\ "5*KRF,0#5EE05
M&.P5([HZ:1S^4\L22T H(. +9V>Q&>F*[Z!"8'@B#W =V,1@N$C@B8WB"3,/
M3T-V"[EBH9@[*Y5SY4JI](7,BNT!I8:1$^(4WSP[.<F=%LYRA9/R^1?4)!J9
M$?@3WR:A;^?SN9-R)5<ZK132V^#;6[4^H1]ROO=#WLD/*>VP'_+>FR/QO:"&
M?RNH]5AK73>NJP_7%V/%,U*($\Q\<YD"NPGNA*928'?",8MHPATX4IC,HTP>
M]@:1X\4?,YW[$U8*XB!T^F+(%3?P0>,W1$BF<7'L%S>.(RM&!G*?A#W/2$YG
M=K.(5%NI\2PBY29UDQ-]"=SH?5TP__AC9>:GNU7,ET.R1Q;+*3PS1I[^(*>%
MHU77T\U04U(195KR6Y/,Q$_%8L+%>/&;]L'UN3<9(B[W9BTUJ4:]<#8JJ)KE
MF/:;KK[LA3=[M=4L:NO&CBZZ<GF^W$XJ46)KPPM@"R\!]YCB:(%[D@0!4I @
M_/8?W=@)*299?>?GRGFDLFM76WA(I5.\%/6* 2/?B(B7CTDFKQ3>R09]%NG'
M['W>)4T'AN+D05>YISZ;#WNYS4$_&*$RM=!*E2_LY39;;ID61@Q[5#_&>$S6
MM37UGF[2O>AFBZ[E=&P=U*$U6L94)_ /-F5NX\J2S11*&65"6O\Z%(\[6MQP
M1";^.RO]C7M=[PXR-LYQW=#Q6  8IAUTK+GEYZ1]% _;W_E+K7PA%V ^\'AD
M)#IS>__95>;R\HIR$9^X96CD2=>8CW.J'T9QKK9\4!P@"[ENDFR:3\5U,/&(
M=^^^^U&"[S&"F,UR9'"RF#0X.2,K9&&D$*[Y4 $/J?'MGZ?;-OG^,SMGIC\*
M@V(:;WE'-QBY99JP SBKNG3Z,.S\JJO>V5RF'K>?/Q2_$2XRH\:PYYYCXNFD
MR.SX0)LY)<,G*8$]?-_3^<?" '/Q;1D6NJYY=Q2B80^XF7>?@5FAJ_SU'; H
M4K[N7PS:XWTJU_?]IT#SY?,C\%E,X-+=W6.S*ABM_M]G8/0T4G\U>)^)F;Z2
MQ1 \S47V^'5Q3W=9VY[BL6JZ0RQY_!@^:;UM?(;-(U@-Z<4'S"H5Z1L>SG%-
MWL=@=S'4TZ3#'C?X\XC4'%VL='C)&IK,LGOZ0/!,,L_,5,A@:,)K V6__H/U
M?YT>\/VH\IAQ@/199+,\C(X26%<4,'' /.LVHS;[7( Z4\H?';O-TU9&)+NB
M4\+'J:E'$!862NABW3+);BE=JBOG]W5_UIOKVMA7_7F?&W?)<US7FMAY-JT8
M5E%C\G D06@_J1%+9,!.$QJP1)R=%:(37FZI;5.UY^#MI'F,;L,LU-O;2=PM
M^ZVKW'.IO3N6[HW+C'QW/7'51&OI),VU-%,$L,&)QLC##?Y;_[DCO+>995$5
MR*,IQU)27J9WN@H^,0(S^'WHX)W6A8\X-D0J)I(QT[1'QBLUP1-+WY78O!:N
M1.K@GVYY%+%RDIP@;S&#):5R1*JVS55=!!*B3QTFYC9+;I0;I;[H^7DI9451
M2551S!<#LMU,R/063SF6W4^!V7=6-P^B4@^6,++GJ9IWIK1=2SM@OP*!9(9"
MFW>@O%$Y5H<]9M(PF7.C4YNE3Q[3FGY6PE1VVH+WP#XTGIK"*=YD_5Q3@E7Z
MG*<;6@W/_MW/;5BPHF",*,<=>?+NWV_/M/_9$G)?98;]%= ]!#JW:_]?V[3#
M#(.2UM#"AM6/5@>4P0,SV1LU7$DNG%ZV%DI!09%+QQ:EZ+9H@N]XGVKC\0QO
MAI.$;K9#:23-8'+W&$<GNVK"\[ V?DWG?30>'*-L2E69XWNG-3O+*[H'AA4\
MN&.IC%PB%8;HOS5MHM<>DEJ>AT=3-VB'U%W]+"K6K%VCS.G#_,XH!@_>%SGZ
MVXZMM_P2\)DF=:QD;N*!E\?__=5.\>\9V1UEGYOBF$W --#2OOZZO-DE,5P:
M8)KPZOQ:\XFWD_<K;LL*U'Z"U2Y+XP<& M07ORCPCU^[Q/V-T^EP]854E'PA
M0X_',4(L:/Z4HL!CX%_<>MG)7=!FO^G<H.+GY-Q1;703)>])$M(_/.\65AD<
MP@X/TD^]T#CN^YW5!6/8J,&L_JYY"8W+I]V=_5"$,-@7P5T[UUE84]6!;1+$
M#ZH;U.Z1FD):/6KU 1?>*@W%$\&W]XQ4I?V\<NJ1KSM'UBL79R2ZR40EV&E%
MB_?:WE62&UI,018'%O1%I4KA^9XXUGTG?9LD<:_V'>.9!7=Z(ZWO5NRR#4FD
MA97,J3$<19:YB$WZ^402:/]3?5C>XKJ/]G)\CV*8&O]8(;_EGTOU8Y5*1.+S
M=G:)2)B87YB=F%_9)^:OF)CO?FN)Y/Q&+KXA3AP5GR$Q/XV=\X%2^"<444*]
M>W9ZM"B>K&(K",NDED:JZ@M")U-"\0@<U<2S][C093+&DM7W2$:Y'UX1=Q%-
M.@ - K/2%!F4L?4<WI'.6QUVD//"&)Y+(Y%/B]XN71N1=9ABBVH\!!CKL@$+
MQ3[SKE#K<86Q-D[OY.+$5-HGW<:F,;JY?>(%O[_/P4>[5U5GX)=5E<5G O>_
MJ4BZ8ZN$;ISN*][M^AHA&TYN]=:);@]M4@<7'AL+KIZ4E2+M/W0#1&WI@"^:
M(1TF$D+NZMM"9;/'3"Z/2<;\DZ8X('B*]D]F(LN_"D5$_0F-Y$Q\LJDN*8N1
MO%;RHJX#2J@3*:HI\)/'6Y>E*)2-'<IR'KB)P\VE"#Q5"I6^1Y#QQ]BWPRLJ
M!+#%TZ;0M<<K0B_WWS#T&B-Q_MW>OVKWC5]B/5ZU;V^^_C]02P,$%     @
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MD=89GP&S#AYSH5S[_]_KYPT27PN1.&3E-,),A)P*GY$2;E$X]"41(K6L+)!
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M>"TR,#$Y,3(P.2YX<V102P$"% ,4    " !AB8Q/L&)M2?P*  #?AP  %
M            @ %K P  9&=X+3(P,3DQ,C Y7VQA8BYX;6Q02P$"% ,4
M" !AB8Q//F=#?4\'   A60  %               @ &9#@  9&=X+3(P,3DQ
M,C Y7W!R92YX;6Q02P$"% ,4    " !AB8Q/FE(X=SX3  !/8P  #P
M        @ $:%@  <W,Q-3DX-31?.&LN:'1M4$L! A0#%     @ 88F,3U ^
M7P6:B@  D;P# !,              ( !A2D  '-S,34Y.#4T7V5X,#$P,2YH
M=&U02P$"% ,4    " !AB8Q/35USK\T(  !;&@  $P              @ %0
LM   <W,Q-3DX-31?97@Y.3 Q+FAT;5!+!08     !@ & ($!  !.O0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
